Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis
Phase: PHASE2
Conditions: Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis
Sponsor: National Cancer Institute (NCI)

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
1 
 
 
 
 
 
 
 
DCP Protocol #: MAY2016-07-01  
 
Local Protocol #: MAY2016-07-01  
 
Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated with 
Familial Adenomatous Polyposis 
 
 
Consortium Name: 
 
 
Cancer Prevention Network (CPN) 
Consortium Lead Investigator:  
Paul J. Limburg, M.D., M.P.H. 
 
 
 
 
 
Professor of Medicine  
 
 
 
 
 
Mayo Clinic College of Medicine 
200 First Street, SW, Rochester, MN  55905 
 
 
 
 
 
Telephone:  507-284-2511 
 
 
 
 
 
Fax:  507-266-4371 
 
 
 
 
 
E-mail:  limburg.paul@mayo.edu 
 
Organization Name: 
 
 
       Mayo Clinic in Arizona  
Protocol Principal Investigator:  
       N. Jewel Samadder, M.D., M.Sc.* 
 
 
 
 
 
       Mayo Clinic in Arizona 
 
 
 
 
 
       13400 East Shea Boulevard 
 
 
 
 
 
       Scottsdale, AZ  85259 
 
 
 
 
 
       Telephone: 480-301-8000 
 
 
 
 
 
       Fax: 480-301-7295 
 
 
 
 
 
       E-mail address: Samadder.jewel@mayo.edu 
 
Organization:  
 
 
       Mayo Clinic 
Statistician: 
 
 
 
       Nathan R. Foster, M.S. † 
 
 
 
 
 
       200 First Street SW, Rochester, MN  55905  
 
       Telephone: 507-284-5051 
 
       Fax:  507-266-4371 
 
       E-mail address: foster.nathan@mayo.edu 
 
* Investigator having NCI responsibility for this protocol  
† Study Contributor(s) not responsible for patient care 
 
ClinicalTrials.gov:  
NCT02961374 
IND Sponsor: 
 
NCI/Division of Cancer Prevention  
IND#:                                 64808 
Agent(s)/Supplier:   
Erlotinib/NCI Division of Cancer Prevention   
NCI Contract #:  
HHSN261201200042I 
Protocol Version Date:  July 22, 2019 
Protocol Revision or  
 
Amendment #  
Amendment 8 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
2 
 
Participating Investigators and Organizations  
Mayo Clinic in Arizona 
13400 East Shea Boulevard 
Scottsdale, AZ  85259 
AZ020  
 
 
 
        
 
N. Jewel Samadder, M.D. 
Telephone: 480-301-8000; Fax: 480-301-7295 
E-mail address: Samadder.jewel@mayo.edu 
 
University of Utah, Huntsman Cancer Institute 
2000 Circle of Hope, Salt Lake City, UT 84112 
UT003  
 
 
 
        
 
Priyanka Kanth, M.D. 
Phone: 801-581-7803; Fax: 801-585-5763 
Email:Priyanka.kanth@hsc.utah.edu 
Marta E. Heilbrun, M.D., M.S., Radiologist 
phone: (801) 581-2868 
Email: marta.helbrun@hsc.utah.edu 
 
Michael Sossenheimer, M.D. 
Phone 801-581-7803; Fax 801-585-5763 
Michael.sossenheimer@hsc.utah.edu 
Mayo Clinic in Minnesota 
200 First Street SW, Rochester, MN  55905 
MN026 
 
Paul J. Limburg, M.D., M.P.H. 
Phone: 507-284-2511; Fax: 507-266-4371 
Email: Limburg.paul@mayo.edu 
Navtej Buttar, M.D. 
Phone: 507-284-2511; Fax: 507-266-4371 
Email: buttar.navtej@mayo.edu 
 
Lisa Boardman, M.D. 
Phone:  507-284-2511; Fax:  507-266-4371 
Email:  boardman.lisa@mayo.edu 
Cleveland Clinic 
9500 Euclid Avenue, Cleveland, OH 44195 
OH027 
 
Carol Burke, M.D. 
Phone: 216-444-6864; Fax: 216-444-6305 
Email: burkec1@ccf.org 
Gautam Mankany, M.D. 
Phone: 216-445-1249; Fax: 216-445-3889 
Email: mankang@ccf.org 
University of Puerto Rico 
P.O. Box 70344, PMB 371 
San Juan PR 00927-8344 
PR008 
 
Oncology Hospital Dr. Isaac Gonzalez 
Barrio Monacillos, Medical Center, Rio Piedras 
P.O. Box 191811 
San Juan PR 00919-1811 
PR021 
 
Marcia Cruz-Correa, M.D., Ph.D. 
Phone: 787-772-8300; Fax: 787-522-3282 
Email: marcia.cruz1@upr.edu 
Priscilla Magno Pagatzaurtundua, M.D. 
University of Puerto Rico 
Phone: 787-344-3775; Fax: 787-522-3282 
Email: Priscilla.magno@upr.edu  
 
Victor L. Carlo, M.D. 
University of Puerto Rico 
Phone:  787-620-8716; Fax:  787-522-3282 
Email:  victor.carlo@upr.edu 
 
Irene Villamil Sanchez, M.D. 
University of Puerto Rico 
Phone:  787-632-4575; Fax:  787-522-3292 
Email:  Irene.villamil1@upr.edu 
University of Michigan, Medical School 
2150A Cancer Center, Ann Arbor, MI  48109 
MI014 
Danielle Turgeon, M.D. 
Phone:  734-764-6860; Fax:  734-936-7392 
Email:  kturgeon@med.umich.edu 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
3 
 
Elena M. Stoffel, M.D., M.P.H. 
Phone: 734-647-1417; Fax: 734-763-7672 
Email: estoffel@med.umich.edu 
MD Anderson Cancer Center 
1515 Holcombe Blvd.  Unit 1360 
Houston, TX 77030 
TX035 
 
Eduardo Vilar-Sanchez, M.D., Ph.D. 
Phone: 713-745-1836; Fax: 713-794-4403 
Email: evilar@mdanderson.org 
Patrick Lynch, J.D., M.D. 
Phone:  713-794-5073; Fax:  713-563-9740 
Email:  plynch@mdanderson.org 
 
Selvi Thirumurthi, M.D., M.S. 
Phone:  713-794-5073; Fax:  713-563-9740 
Email:  sthirumurthi@mdanderson.org 
 
Margaret Dunseith, PA 
Phone:  713-745-1019; Fax: 713-563-9740 
Email: mmcguire2@mdanderson.org 
University of Pittsburgh Medical Center   
200 Lothrop Street, Pittsburgh, PA  15213 
PA015 
 
Rohit Das, M.D. 
Phone: 412-864-7091; Fax: 412-864-7080 
Email: dasr@upmc.edu 
Robert Schoen, M.D., M.P.H. 
Phone: 412-648-7086; Fax: 412-648-7080 
Email: rschoen@pitt.edu 
 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
4 
 
Contacts 
Questions: 
Contact Name: 
Test schedule, Intervention 
Delays/Interruptions/Adjustments 
Adverse events 
Michelle Westover, CCRP, Lead Study Coordinator 
Huntsman Cancer Institute, University of Utah 
Phone:  801-581-4066     Fax: 801-585-5763 
Email: michelle.westover@hci.utah.edu  
Serious Adverse Event reporting 
See Protocol Section 11.2 
Subject eligibility, Forms completion, 
paraffin-embedded specimens 
April Felt 
CPN Research Base Data Manager and Pathology Coordinator 
Phone: 507-538-0268    Fax: 507-266-3722 
E-mail:  felt.april@mayo.edu 
CPN Lead Site Coordinator 
Colleen Akerley 
CPN Research Base Senior Program Coordinator 
Phone: 507-284-2180     Fax: 507-266-4371 
E-mail: akerley.colleen@mayo.edu 
Protocol Development 
Sharon Kaufman 
CPN Research Base Senior Research Protocol Specialist 
Phone: 507-293-1605     Fax: 507-266-4371 
E-mail: kaufman.sharon@mayo.edu  
Regulatory 
Administrative 
Patty Simonson 
CPN Research Base Research Protocol Specialist 
Phone:  507-266-2218    Fax:  507-266-4371 
E-mail:  Simonson.patricia1@mayo.edu   
Registration 
 
CPN Registration Office (8:00-4:30 Central Time) 
Phone: 507-284-4130; Fax: 507-284-0885 
E-mail: random01@mayo.edu 
Monitoring 
Education 
Anne Holland 
CPN Research Base Compliance Coordinator 
Email:  holland.anne@mayo.edu 
Phone : 507-293-7795 
All other biospecimens  
BAP/Biospecimens collection, kits,  
and shipment 
Roxann Neumann, RN, BSN, CCRP 
CPN Research Base Biospecimen Resource Manager 
Phone: 507-538-0602; E-mail: Neumann.roxann@mayo.edu 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
5 
 
SCHEMA 
 
Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated with 
Familial Adenomatous Polyposis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study Population 
• 
Familial Adenomatous Polyposis (Classic or Attenuated),  
• 
Duodenal polyposis, Spigelman stage 2-3 
• 
Females and males ≥ 18 years of age and ≤69 years of age 
Informed Consent and Pre-Registration (n=70) 
Screen 1 (n=70) 
• 
Physical exam, medical/surgical history 
• 
Alcohol and tobacco use assessments 
• 
Baseline symptoms, concomitant medications 
• 
Blood chemistry and hematology, pregnancy test (if applicable), urinalysis 
• 
Research blood and urine collection 
Screen 2 (n=70) 
• 
Esophagogastroduodenoscopy (EGD) and lower gastrointestinal (GI) 
endoscopy 
• 
Biopsies and tattooing (See Section 7.3) 
Registration (n=60) 
Month 1 Visit (+/- 4 days) 
• 
Adverse events and concomitant medications assessment 
• 
Review of medication diary 
• 
Brief physical exam 
• 
Clinical blood tests and urinalysis 
Intervention (n=60) 
Erlotinib 350 mg/week x 6 months (without food) 
Monthly Telephone/Email Contact 
• 
Months 2, 4, 5 (+/- 7 days) 
• 
Adverse events and concomitant medications assessment 
• 
Review of medication diary 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
6 
 
 
 
Follow-Up Telephone/Email Contact at Month 7 (+/- 10 days)  
• 
Adverse events and concomitant medications assessment 
• 
Repeat blood tests if any abnormal results at Month 6 
Primary Endpoints (n=50 evaluable) 
 
Polyp Burden:   To assess the mean percent change in duodenal polyp burden 
(sum of diameters from all polyps) from baseline to 6 months post-intervention 
for FAP subjects receiving weekly erlotinib.  The hypothesis is that weekly 
erlotinib will significantly reduce duodenal polyp burden after 6 months of 
treatment.   
 
Adverse events (if polyp burden shows a significant decrease from baseline):  To 
assess the grade 2/3 adverse event rate in this population and compare it to 
historical data.  The hypothesis is that weekly erlotinib will significantly reduce 
the grade 2/3 AE rate compared to historical control data.  
Month 3 (+/- 7 days) 
• 
Physical exam 
• 
Adverse events and concomitant medications assessment 
• 
Review of medication diary 
• 
Collect unused medication and dispense new supply 
• 
Clinical blood tests, urinalysis, research blood and urine collection 
• 
Pregnancy test, if applicable 
Post-Intervention Visit/Month 6 (+/- 10 days) (n=60) 
• 
Physical exam 
• 
Adverse events and concomitant medications assessment 
• 
Alcohol and tobacco use assessments 
• 
Collect unused medication and medication diary 
• 
Clinical blood tests, urinalysis, research blood and urine collection 
• 
EGD and lower GI endoscopy with biopsies 
• 
Pregnancy test, if applicable 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
7 
 
TABLE OF CONTENTS     
 
Cover page .................................................................................................................................................... 1 
Investigators .................................................................................................................................................. 2 
Contacts ........................................................................................................................................................ 4 
Schema .......................................................................................................................................................... 5 
 
1. Objectives 
1.1 Primary objectives................................................................................................................................. 10 
1.2 Secondary objectives ............................................................................................................................ 10 
 
2. Background 
2.1 Familial Adenomatous Polyposis (FAP) ................................................................................................. 10 
2.2 Erlotinib (Tarceva®) ............................................................................................................................... 11 
2.3 Rationale ............................................................................................................................................... 12 
 
3. Summary of Study Plan ........................................................................................................................... 12 
 
4. Participant Selection 
4.1 Pre-Registration Inclusion Criteria ........................................................................................................ 14 
4.2 Pre-Registration Exclusion Criteria ....................................................................................................... 14 
4.3 Registration Inclusion Criteria ............................................................................................................... 15 
4.4 Registration Exclusion Criteria .............................................................................................................. 16 
4.5 Inclusion of Women and Minorities ..................................................................................................... 16 
4.6 Recruitment and Retention plan .......................................................................................................... 16 
 
5. Agent Administration 
5.1 Dose regimen and dose groups ............................................................................................................ 17 
5.2 Erlotinib administration ........................................................................................................................ 17 
5.3 Run-in procedures ................................................................................................................................. 17 
5.4 Contraindications .................................................................................................................................. 17 
5.5 Concomitant medications ..................................................................................................................... 17 
5.6 Dose modification ................................................................................................................................. 18 
5.7 Adherence/compliance ......................................................................................................................... 20 
 
6. Pharmaceutical Information 
6.1 Erlotinib; IND# 64808; IND Sponsor:  NCI, DCP ..................................................................................... 21 
6.2 Reported adverse events and potential risks ....................................................................................... 21 
6.3 Availability ............................................................................................................................................. 25 
6.4 Agent distribution ................................................................................................................................. 25 
6.5 Agent accountability ............................................................................................................................. 25 
6.6 Packaging and labeling .......................................................................................................................... 25 
6.7 Storage .................................................................................................................................................. 26 
6.8 Pre-Registration and Registration ......................................................................................................... 26 
6.9 Blinding and unblinding methods ......................................................................................................... 27 
6.10 Agent description/disposal ................................................................................................................. 27 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
8 
 
7. Clinical evaluations and procedures 
7.1 Schedule of events ................................................................................................................................ 28 
7.2 Baseline testing/Prestudy evaluation ................................................................................................... 30 
7.3 Evaluation during study intervention ................................................................................................... 30 
7.4 Evaluation at completion of study intervention ................................................................................... 31 
7.5 Post-intervention follow-up period ...................................................................................................... 31 
7.6 Methods for clinical procedures ........................................................................................................... 31 
 
8. Criteria for evaluation and endpoint definition 
8.1 Primary endpoint .................................................................................................................................. 33 
8.2 Secondary endpoints ............................................................................................................................ 33 
8.3 Off-agent criteria ................................................................................................................................... 34 
8.4 Off-study criteria ................................................................................................................................... 34 
8.5 Study termination ................................................................................................................................. 35 
 
9. Correlative/special studies 
9.1 Rationale for methodology selection .................................................................................................... 35 
9.2 Comparable methods ............................................................................................................................ 35 
 
10. Specimen management 
10.1 Laboratories ........................................................................................................................................ 35 
10.2 Collection and handling procedures ................................................................................................... 36 
10.3 Labeling and Shipping instructions ..................................................................................................... 39 
10.4 Tissue banking ..................................................................................................................................... 39 
 
11. Reporting adverse events 
11.1 Adverse events .................................................................................................................................... 40 
11.2 Serious adverse events ....................................................................................................................... 41 
 
12. Study monitoring 
12.1 Data management .............................................................................................................................. 43 
12.2 Case report forms ............................................................................................................................... 43 
12.3 Source documents .............................................................................................................................. 43 
12.4 Data and safety monitoring plan ........................................................................................................ 44 
12.5 Sponsor or FDA monitoring................................................................................................................. 44 
12.6 Record retention ................................................................................................................................. 44 
12.7 CRADA/CTA ......................................................................................................................................... 44 
 
13. Statistical considerations 
13.1 Study design/description .................................................................................................................... 44 
13.2 Randomization/stratification .............................................................................................................. 45 
13.3 Accrual and Feasibility ........................................................................................................................ 45 
13.4 Primary objective, endpoint, analysis plan ......................................................................................... 46 
13.5 Secondary endpoints .......................................................................................................................... 47 
13.6 Reporting and exclusions .................................................................................................................... 48 
13.7 Evaluation of toxicity........................................................................................................................... 48 
13.8 Evaluation of response ........................................................................................................................ 49 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
9 
 
13.9 Interim Analysis ................................................................................................................................... 49 
13.10 Ancillary studies ................................................................................................................................ 49 
 
14. Ethical and regulatory considerations 
14.1 FDA form 1572 .................................................................................................................................... 50 
14.2 Other required documents ................................................................................................................. 50 
14.3 Institutional review board approval ................................................................................................... 50 
14.4 Informed consent ................................................................................................................................ 50 
14.5 Submission of regulatory documents ................................................................................................. 51 
14.6 Other ................................................................................................................................................... 51 
 
15. Financing, expenses, and/or insurance ................................................................................................. 52 
 
References .................................................................................................................................................. 52 
 
Summary of Changes – Informed Consent Form ........................................................................................ 54 
 
Consent form template for consortia cancer chemoprevention trials ....................................................... 55 
 
Appendices 
Appendix A. ECOG Performance Status ...................................................................................................... 74 
Appendix B. Medication and Symptom Diary ............................................................................................. 75 
Appendix C. Was It Worth It (WIWI) Questionnaire ................................................................................... 78 
Appendix D. Alcohol and Tobacco Use Assessments .................................................................................. 79 
Appendix E. Alcohol and Tobacco Use Cessation Resources ...................................................................... 86 
Appendix F. Diary of Medications Used for Acid Reflux Symptoms ........................................................... 88 
 
 
 
 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
10 
 
1. 
OBJECTIVES 
 
1.1 
Primary Objectives  
 
• 
Polyp Burden:   To assess the mean percent change in duodenal polyp burden (sum of diameters 
from all polyps) from baseline to 6 months post-intervention for FAP subjects receiving weekly 
erlotinib.  The hypothesis is that weekly erlotinib will significantly reduce duodenal polyp burden 
after 6 months of treatment.   
• 
Adverse events (if polyp burden shows a significant decrease from baseline):  To assess the 
grade 2/3 adverse event rate in this population and compare it to historical data.  The 
hypothesis is that weekly erlotinib will significantly reduce the grade 2/3 AE rate compared to 
historical control data.  
 
1.2 
Secondary Objectives  
 
• 
To evaluate all adverse events  at least possibly attributed to  weekly erlotinib; 
• 
To assess the absolute and percent change in duodenal polyp number from baseline to 6 
months;   
• 
To assess the absolute and percent changes in lower gastrointestinal polyp burden and number 
for the subset of participants with ileal pouch anal anastomosis (IPAA) or ileo-rectal anastomosis 
with rectal stump (anticipated to be approximately 70% of registered cohort); and 
• 
To assess the absolute and percent change in desmoid tumor size in participants who have 
baseline and follow up CTs performed as part of their standard of care (anticipated to be 
approximately 30% of the registered cohort); 
• 
Gene expression profiles in duodenal adenomas and uninvolved tissue will be compared 
between baseline and endpoint samples using negative binomial statistics (DESeq2): 
o Identify differentially expressed genes between duodenal polyps and uninvolved tissue 
at endpoint compared to baseline; 
o Evaluate the effect of weekly erlotinib on EGFR and Wnt target gene expression in 
duodenal adenomas; 
o Evaluate the effect of weekly erlotinib on immune response signaling in duodenal 
adenomas and uninvolved tissue. 
 
2. 
BACKGROUND 
 
2.1 
Familial Adenomatous Polyposis (FAP) 
 
Multiple studies have shown that the 
cyclooxygenase (COX) inhibitor, sulindac, a 
nonsteroidal anti-inflammatory drug (NSAID), 
significantly inhibits colorectal adenomatous polyps 
in FAP patients.1, 2 However, NSAIDs have 
demonstrated considerably less efficacy with 
respect to duodenal adenoma burden, based on a 
limited number of studies to date.3, 4  Celecoxib use 
resulted in a modest reduction of duodenal5 and 
Figure 1. Effects of sulindac and erlotinib on 
signaling pathways, based on studies to date. 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
11 
 
colorectal polyps,6, 7 but is no longer FDA-approved for this indication.8  Studies have suggested that APC 
inactivation and epidermal growth factor receptor (EGFR) signaling promote COX-2 expression and the 
subsequent development of intestinal neoplasia.9, 10  Convergence between the Wnt and EGFR signaling 
pathways and COX-2 activity was demonstrated in a mouse model of FAP, in which a combination of 
sulindac and an EGFR inhibitor diminished small intestinal adenoma development by 87%.11  Normally, 
APC down-regulates β−catenin through a complex with Axin, CK1, and GSK-3β. Mutational inactivation 
of APC results in the accumulation and nuclear translocation of β−catenin where it interacts with TCF-
4/LEF-1 transcription factors to activate genes whose products mediate proliferation, survival, and 
migration. Despite the fact that APC is mutated in the vast majority of colorectal adenomas and 
adenocarcinomas in humans, careful examination of human colorectal tumors in multiple studies have 
shown that nuclear β−catenin is found in only a small minority of microscopic and larger adenomas, 
compared with approximately half of adenocarcinomas. Thus, constitutive activation of the canonical 
WNT signaling pathway appears to increase progressively during the adenoma-carcinoma sequence in 
the gut. However, the molecular events downstream of APC mutation at the early stages of neoplastic 
transformation are not entirely explained by the current model.  Prior studies from our group document 
that germline mutation of apc in zebrafish leads to a loss of retinoid synthesis in colorectal tissue early in 
the formation of polyps. This loss of retinoid expression is β−catenin-independent and results in the up-
regulation of cyclo-oxygenase 2 (COX-2) in intestinal tissue (see Figure 1). COX-2 has been shown to 
drive the expression and release of growth factors, such as TGFα, and inflammatory mediators 
(prostaglandins, thromboxane, and prostacyclin), and, is a key target of chemopreventive agents.  An 
important target downstream of COX-2 is the epidermal growth factor receptor (EGFR).  Preliminary and 
previous studies by Jones et al. show that germline APC mutation alone is insufficient to cause nuclear 
localization of β−catenin and hence canonical WNT signaling in preneoplastic intestinal tissue and early 
adenomas.  Jones et al. showed that co-activation of EGFR-RAS-MEK signaling is required for the nuclear 
localization of β−catenin. Furthermore, EGFR activation increases COX-2 expression leading to 
reinforcement of EGFR activation and signaling. Progressive mutational events, namely, loss of 
heterozygosity of APC and oncogenic activation of KRAS, further reinforce COX-2 and EGFR signaling 
crosstalk. 
 
FAP patients are at greatly increased risk for duodenal neoplasia, with duodenal adenomas eventually 
forming in >50% of FAP patients and duodenal adenocarcinoma occurring in up to 12%.12-17  In fact, 
following colectomy, duodenal adenocarcinoma is the leading cause of cancer death in FAP patients. 
Unfortunately, endoscopic and surgical interventions are often challenging and suboptimal with respect 
to preventing invasive malignancy.18, 19  Therefore, it is imperative that more effective duodenal cancer 
prevention/control strategies be developed for patients with FAP.  Building on positive findings from the 
recently completed FAPEST trial, further definition of an effective, well-tolerated dosing regimen for 
erlotinib could favorably impact FAP standard of care with consequent improvements in morbidity, 
mortality, and quality of life. 
 
2.2 
Erlotinib (Tarceva® NDA-021743) 
 
Erlotinib (Tarceva®, NDA-021743), an FDA-approved tyrosine kinase inhibitor, directly and reversibly 
inhibits the human EGFR tyrosine kinase with an IC50 of 2 nM (0.79 ng/mL) in an in vitro enzyme assay 
and reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM (7.9 ng/mL).  This 
potent inhibition is selective for the EGFR tyrosine kinase.  Standard targeted therapy dosing ranges 
from 100-150 mg/day, based on pharmacokinetic studies showing an average plasma concentration of 
500ng/mL, which is targeted for clinical efficacy when treating existing cancer. 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
12 
 
 
2.3 
Rationale 
 
In our prior “Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients” trial (FAPEST; 
NCT01187901), erlotinib at 75 mg/day was investigated and found to be associated with marked 
duodenal neoplasia regression (further described in section I) recently published in the Journal of the 
American Medical Association.20  However, agent tolerability was limited by acneiform rash and oral 
mucositis. This resulted in dose reductions, leading to FAPEST participants receiving an average erlotinib 
dose of 50 mg/day.  Another recent clinical trial in individuals with advanced premalignant head and 
neck lesions determined that erlotinib 50 mg/day was the maximum tolerated dose with minimal 
observed toxicity yet retained histologic remission.21  Preclinical 22 and early phase clinical trial23, 24 data 
suggest that intermittent, once weekly dosing of erlotinib (seven times the daily dose) yields clinical 
efficacy with fewer adverse effects, offering intriguing potential for chemopreventive application. Based 
on these findings, we propose to evaluate the efficacy and tolerability of erlotinib 350 mg/week as a 
candidate intervention for duodenal polyp regression in patients with familial adenomatous polyposis 
(FAP). 
 
Increasing evidence suggests that tobacco and alcohol use are risk factors in the development of 
intraepithelial neoplasia and cancer. In addition, tobacco and alcohol use may adversely affect agent 
intervention, for example by altering the safety profile or metabolism of a drug. Standardized 
assessments of tobacco and alcohol use during clinical trials will aid in understanding the potential 
relationship between the use of these products and clinical endpoints or cancer prevention biomarkers. 
Therefore, NCI, DCP is including assessment of tobacco and alcohol use at baseline and Month 6, to 
determine the potential impact of tobacco and alcohol use on 1) treatment toxicity and symptom 
burden, and 2) the efficacy of treatment intervention. 
 
3. 
SUMMARY OF STUDY PLAN 
 
General overview: We will evaluate the efficacy and toxicity of a 6-month intervention of erlotinib 350 
mg/week in FAP patients (see Schema). Change in duodenal polyp burden (comparing post-intervention 
vs. baseline) will be assessed by esophagogastroduodenoscopy (EGD), utilizing field tested measurement 
protocols applied in our recently completed FAPEST study, and will serve as the primary endpoint.  
Adverse events will be monitored and reported according to NCI CTCAE v. 4.0 criteria.  The proposed 
trial will also provide a unique opportunity to generate novel data regarding the RNA transcriptome in 
FAP patients, based on RNA sequencing (RNA-Seq) technology.  RNA-Seq will be performed on 
uninvolved duodenal mucosal biopsy specimens obtained at the baseline and post-intervention EGD 
exams (placed in RNA Later and stored at -80°C prior to RNA isolation).  These molecular studies will 
facilitate characterization of participant response at the cellular level and will also offer new insights 
pertaining to the molecular mechanisms of duodenal polyp growth/regression.  Additional changes in 
duodenal and colorectal polyps will also be measured and compared between intervention arms as 
secondary endpoints.   
 
Baseline Evaluation: Prior to registration, willing, consented participants will be screened in two stages, 
as outlined below. 
 
Screening 1: Individuals with FAP (classic or attenuated) will be identified from clinical practice and 
existing registries.  Willing, eligible trial participants will be consented (see Schema) and will undergo 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
13 
 
physical exam; medical/surgical history; alcohol and tobacco use assessment; blood chemistry and 
hematology testing; pregnancy test, if applicable; symptom and concomitant medication assessments; 
urinalysis, and research blood draw and urine collection. 
 
Screening 2:  Esophagogastroduodenoscopy (EGD) will be performed to evaluate the duodenum using 
forward-viewing and/or side-viewing techniques (with still and video documentation). 
 
A tattoo will be placed 10 cm distal to the duodenal bulb to define a region heretofore referred to as the 
duodenal segment, which will extend from the duodenal bulb distally to point of the tattoo. Endoscopic 
tattooing has been widely employed in previous research protocols and is clinically advocated by many 
authorities.25, 26  For willing participants who are undergoing lower endoscopy for clinical purposes, 
rectal/pouch polyps may also be measured and recorded. 
 
During the baseline endoscopy procedures, one polyp will be sent to the local pathology laboratory for 
histological analysis, since this assessment is an inherent component of the Spigelman stage 
categorization for duodenal polyps.  Remaining polyps will be sampled but not removed (unless clinically 
required) from the 10 cm duodenal segment and rectum/pouch.  Any lesions containing high-grade 
dysplasia or cancer will result in study exclusion and will be managed with appropriate surgical or 
oncology referral(s).  All endoscopy exams will be recorded in high definition using Medicapture (or 
comparable) recorders to allow for blinded review as a future secondary endpoint. 
 
On Study:  60 eligible participants will be assigned to an intervention of erlotinib 350 mg once weekly 
without food. Study agents will be self-administered for a period of 6 months.  Participants will return 
for a visit at Month 1 (+/- 4 days) for brief physical exam, adverse events assessment (especially 
weakness, fatigue, rash, diarrhea, abdominal pain, melena, hematochezia, nausea, vomiting), 
concomitant medications review, and blood and urine tests.  Participants will be contacted monthly 
(Months 2, 4, and 5) by the study coordinator to ensure medication compliance and record adverse 
events. A diary of compliance and symptoms will be maintained by participants and reviewed during an 
office visit at 3 months (+/- 7 days).  The Month 3 study visit will also include a physical exam, urinalysis, 
pregnancy test (if applicable), and blood draw for safety and toxicity monitoring, as well as research. 
Concomitant medications, adverse events, and medication compliance will also be reviewed.  
Throughout the intervention period, participants will be provided with “adverse event medications” to 
counteract anticipated symptoms associated with the study agents, based on observations from the 
FAPEST study. 
 
Post-Intervention:  At the Month 6 visit (+/- 10 days) or early termination, participants undergo a 
physical exam, adverse event and concomitant medication assessments, laboratory studies, urinalysis, 
repeat pregnancy test (if applicable), follow up alcohol and tobacco use assessments, and research 
blood draw and urine collection.  EGD and lower GI endoscopy with biopsies will be performed 
according to the same protocols applied at baseline.  A follow up phone call will take place at month 7 
(+/- 10 days) to assess adverse events and repeat any blood tests that were outside of institutional limits 
of normal at Month 6. Any reported SAEs will be followed to resolution. 
 
 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
14 
 
4. 
PARTICIPANT SELECTION 
 
4.1 
Pre-Registration Inclusion Criteria 
 
4.1.1 
Diagnosis of familial adenomatous polyposis (FAP) or attenuated familial adenomatous 
               polyposis (AFAP), defined as at least one of the following: 
• 
Genetic diagnosis with confirmed APC mutation (clinical CLIA certified lab or research testing) 
• 
Obligate carrier 
• 
Clinical diagnosis of classic FAP with ≥ 100 colorectal adenomas status post colectomy and a 
family history of FAP 
• 
Clinical diagnosis of FAP, based on personal and family history. Note:  This criterion requires 
documented review and agreement from either the Study Chair or the CPN Lead Investigator. 
 
4.1.2 
Age ≥18 and ≤69 years of age.  Note: Because no dosing or adverse event (AE) data are 
               currently available on the use of erlotinib in participants <18 years of age, children are excluded 
               from this study but will be eligible for future pediatric trials, if applicable. 
 
4.1.3     Ability to understand and the willingness to sign a written informed consent document 
 
4.1.4     Willing to discontinue taking NSAIDS for 30 days prior to initiation of and during 
              intervention.  Exception: Use of ≤ 81 mg daily or ≤ 650 mg weekly aspirin is allowed. 
 
4.1.5    Willing to discontinue smoking for the duration of study intervention 
 
4.1.6    Willing to provide mandatory biospecimens as specified in the protocol 
 
4.2 
Pre-Registration Exclusion Criteria 
 
4.2.1   Any prior treatment with erlotinib or other agent whose primary mechanism of action is known to 
            inhibit EGFR 
 
 
4.2.2   History of allergic reactions attributed to compounds of similar chemical or biologic composition 
            to erlotinib 
 
4.2.3   Use of potent CYP3A4 inhibitors, including but not limited to ketoconazole, atazanavir,  
            clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, 
            troleandomycin, voriconazole, and grapefruit or grapefruit juice 
 
4.2.4   Use of potent CYP3A4 inducers, including but not limited to rifampicin, rifabutin, rifapentine, 
            phenytoin, carbamazepine, phenobarbital, and St. John's Wort 
 
4.2.5   Use of any other investigational agents ≤ 12 weeks prior to pre-registration. 
 
4.2.6     Uncontrolled intercurrent illness or recent surgical procedure that in the opinion of the  
              investigative team would limit compliance with study requirements, including, but not limited  
              to: 
• 
Ongoing or active infection 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
15 
 
• 
Symptomatic congestive heart failure 
• 
Myocardial infarction ≤ 6 months prior to intervention 
• 
Severely impaired lung  function 
• 
Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized 
by the treatment with study intervention 
• 
Diagnosed liver disease, such as cirrhosis, chronic active hepatitis, or chronic persistent 
hepatitis 
• 
Unstable angina pectoris 
• 
Cardiac arrhythmia 
• 
Psychiatric illness/social situations  
 
4.2.7   History of invasive malignancy ≤ 3 years prior to pre-registration.  Exception: adequately treated  
            carcinoma of the cervix, carcinoma in situ, or basal or squamous cell carcinomas of the skin. 
 
4.2.8    Individuals on anticoagulation medications who cannot safely discontinue the medication for at 
             least 48 hours prior to the study endoscopy, as determined by the study investigator and/or 
             participant’s primary healthcare provider. 
 
4.2.9   History of any upper GI  surgery that does not permit access to or evaluation of a 10 cm segment  
            of the duodenum that includes the duodenal bulb, i.e. Whipple Procedure or similar 
 
4.3 
Registration Inclusion Criteria 
 
4.3.1 
ECOG performance status ≤1 (See Appendix A) 
 
4.3.2 
Adequate bone marrow and organ function: 
 
• 
Leukocytes (WBC)  ≥ 3,000/uL (≥ 2,500/uL for African-American participants) 
• 
Platelet count ≥ 100 x 109/L 
• 
Hemoglobin ≥ 11.5 g/dL  
• 
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) 
• 
Alkaline phosphatase ≤ 1.5 x institutional upper limit of normal (ULN) 
• 
AST/SGOT ≤ 2 x institutional upper limit of normal (ULN) 
• 
ALT/SGPT ≤ 2 x institutional upper limit of normal (ULN) 
• 
Creatinine ≤ institutional upper limit of normal (ULN) 
• 
Urinary testing results within institutional limits of normal or deemed clinically insignificant. 
 
4.3.3  Spigelman 2-3 
 
4.3.4 
Not pregnant or breast feeding.  Note:  The effects of erlotinib (Tarceva ®) on the developing 
               human fetus at the recommended therapeutic dose are unknown. For this reason, women of 
               child-bearing potential and men must agree to use adequate contraception (hormonal or  
               barrier method of birth control; abstinence) prior to study entry and for the duration of study 
               participation. Should a woman become pregnant or suspect she is pregnant while participating 
               in this study, she should inform her study physician immediately. Breastfeeding should be 
              discontinued if the mother is treated with erlotinib. 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
16 
 
4.3.5   Willing to use adequate contraception to avoid pregnancy or impregnation until 2 weeks 
            after discontinuing study agent 
 
4.4   
Registration Exclusion Criteria 
 
4.4.1   Histologically-confirmed high grade dysplasia (HGD), cancer, or polyp burden that is not 
            quantifiable. 
 
4.4.2   Regular (≥ 2 times per week) use of drugs that alter the pH of the GI tract, such as proton pump 
            inhibitors (PPI) and antacids.  Exceptions:  Individuals who use prescription PPIs and have 
            approval from their primary health care provider to replace the PPI with an H2 receptor agonist, 
            i.e. ranitidine, for the duration of the trial will be eligible. See Section 5.5 for details.  
 
4.4.3   Gastrointestinal bleeding.  Note that the presence of any symptoms (dyspnea, fatigue, angina, 
            weakness, malaise, melena, hematochezia, hematemesis, anemia, abdominal pain) will require 
            clinical assessment to rule out gastrointestinal bleeding. 
 
4.5 
Inclusion of Women and Minorities 
 
Both men and women and members of all races and ethnic groups are eligible for this trial.  Participants 
may be English-speaking or non-English-speaking. The Participating Organizations (POs) were chosen, in 
part, based on access to the target participant population and access to potential participants of diverse 
backgrounds.  Refer to each PO’s Recruitment, Retention, and Adherence (RR&A) Plan for details. 
 
4.6 
Recruitment and Retention Plan 
 
Each Participating Organization will be required to develop and submit a study- and site-specific RR&A 
plan for the purposes of insuring equal access to the clinical trial by individuals of all genders, races, and 
ethnic groups and for attaining the organization’s accrual target.  POs will use the RR&A Plan Worksheet 
as the basis for their plans.  Each PO will be asked to provide a monthly accrual target.  The CPN 
Operations team will monitor progress toward that target and request revised/corrective RR&A plans if 
necessary, RR&A plans will be reviewed quarterly, at a minimum, in accordance with a master accrual 
target plan developed cooperatively between the CPN and DCP teams. 
 
In general, site study teams will be identified by the site PI.  With assistance from the CPN Operations 
Office, training in study implementation and roles in the RR&A plan will be provided by the site PI or 
designee.  Potential participants will be identified by site study teams by review of existing hereditary 
gastrointestinal cancer registries, clinical referral, family expansion, and self-referral.  In all cases, only 
individuals who have consented to being contacted for future research will be contacted regarding this 
clinical trial. The trial will be posted on clinicaltrials.gov and, if applicable, each of the institutions’ 
clinical trial web sites.  Participant consent, screening, and study visits will be implemented per protocol 
and per institutional policies and procedures. Study teams will maintain contact participants per 
protocol to improve compliance, retention, and adherence. 
 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
17 
 
5. 
AGENT ADMINISTRATION 
 
Intervention will be administered on an outpatient basis. Reported AEs and potential risks are described 
in Section 6.2.  
 
5.1 
Dose Regimen and Dose Groups 
 
Erlotinib (Tarceva®), 350 mg once per week for 6 months. 
 
5.2 
Erlotinib Administration 
 
• 
Participants will be dispensed erlotinib at the time of Registration and at the Month 3 visit. 
• 
At each time point, participants will be dispensed 30 tablets of erlotinib 150 mg and 30 tablets 
of erlotinib 25 mg.   
• 
Participants will self-administer one weekly dose consisting of two 150 mg tablets and two 25 
mg tablets.  If a dose reduction is indicated (see Section 5.6), the participant will take one 150 
mg tablet and one 25 mg erlotinib tablet. 
• 
Erlotinib will be taken with 200 mL of water on the same day and approximately the same time 
each week.  This will be done at least one hour before or two hours after any food intake. 
 
5.3 
Run-in Procedures  
 
There will be no run in procedures. 
 
5.4 
Contraindications 
 
• 
Smoking (Urine cotinine testing will be done pre- and post-intervention to monitor exposure to 
smoke) 
• 
Medications that alter the pH of the upper GI tract, such as PPIs and antacids  
 
5.5 
Concomitant Medications 
 
Patients who are being concomitantly treated with potent CYP3A4 inducers will not be eligible for this 
study.  Potent CYP3A4 inhibitors include, but are not limited to ketoconazole, atazanavir, clarithromycin, 
indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, 
voriconazole, and grapefruit or grapefruit juice.  Potent CYP3A4 inducers include but are not limited to 
rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, and St. John's Wort. 
 
Drugs that alter the pH of the upper GI tract may alter the solubility of erlotinib and reduce its 
bioavailability.  Coadministration of erlotinib with omeprazole, a proton pump inhibitor (PPI), decreased 
the erlotinib exposure and maximum concentration by 46% and 61%, respectively; therefore, the 
concomitant use of proton pump inhibitors with erlotinib should be avoided.  Individuals who take 
prescription PPIs at the time of registration, who, in the clinical judgement of the investigator, can safely 
transition off the PPI to an H2 receptor agonist (i.e. ranitidine), and can tolerate not taking the H2 
blocker on the day before and the day of erlotinib dosing can be eligible. 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
18 
 
Altered coagulation parameters and infrequent reports of bleeding events, including gastrointestinal 
and non-gastrointestinal bleeding, have been reported in patients in erlotinib clinical studies, some 
associated with concomitant warfarin administration. Patients taking anticoagulants will be excluded 
from study participation if, in the opinion of the study investigator and/or primary health care provider, 
they cannot safely discontinue the medications for at least 48 hours prior to the endoscopy procedures.   
 
Patient must discontinue taking any NSAIDS (including sulindac) within thirty days (30 days) of treatment 
initiation. However, patients using 81 mg daily aspirin or 650 mg aspirin not more than once a week are 
eligible.  
 
All medications (prescription and over-the-counter), vitamin and mineral supplements, and/or herbs 
taken by the participant will be documented on the concomitant medication CRF and will include: 1) 
start and stop date, dose and route of administration, and indication. Medications taken for a procedure 
(e.g., biopsy) should also be included. 
 
5.6 
Dose Modification 
 
This study will utilize the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 4.0 for 
toxicity and Serious Adverse Event reporting.  A copy of the CTCAE can be found at 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm 
 
Dose reduction or interruption of erlotinib for toxicity may take place at any time during the study at the 
discretion of the investigator.  Toxicity grading is based on NCI-CTCAE, v 4.0.  Dose level reductions are 
presented in Table 1.  If participants do not tolerate the second erlotinib dose reduction, treatment is to 
be discontinued.  
 
Table 1 
Dose Level Reductions 
Drug 
Starting Dose  
First Reduction 
Second Reduction 
Erlotinib 
350 mg  
once per week 
175 mg  
once per week 
0 mg/week 
(intervention 
holiday) 
 
Erlotinib specific toxicities: 
Dose reductions may be implemented at the discretion of the investigator.  At the discretion of the 
treating physician and when it is in the best interests of the study participant, a dose holiday can be 
implemented even prior to a dose reduction.  Recommendations for dose reductions due to adverse 
events are as follows: 
 
All study participants will be advised to use loperamide or comparable medication at the earliest onset 
of diarrhea.  All study participants will be provided with prescriptions for alcohol-free emollient cream, 
oral antibiotics (tetracycline, minocycline, or doxycycline), topical clindamycin, diphenhydramine, topical 
or oral corticosteroids at discretion of investigator. These are to be used as needed to manage expected 
symptoms.  It is estimated that approximately 30% of participants may require eye drops or stronger 
antibiotics for symptom management. 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
19 
 
Management of a tolerable Grade 2 or 3 rash should include continuation of erlotinib at the current 
dose and symptomatic management.  If skin rash is intolerable, dose reduction according to Table 2 
should be considered.  When skin toxicity improves by at least one grade level, the dose may be 
re-escalated as tolerated.  In Phase II trials, this approach enabled dose re-escalation for the majority of 
participants requiring dose reduction for skin toxicity.  Participants experiencing Grade 4 skin toxicity 
should be discontinued from study treatment.     
 
A detailed flow diagram for management of erlotinib-related rash is available on the CPN website at this 
location: https://cancerpr.ipower.com/member/MAY2016-07-01.shtml   See Protocol Section 8.3 for 
information regarding follow-up activities for participants who, due to adverse events, must discontinue 
study agent before study completion. 
 
For Grade 1 or 2 diarrheas, early intervention should include continuation of erlotinib at the current 
dose and initiation of loperamide therapy as described in Table 2.  Grade 2 diarrhea that persists over 
48–72 hours, despite optimal medical management, should be managed by dose reduction according to 
Table 2.  Participants experiencing Grade 3 diarrhea should interrupt erlotinib until resolution to Grade 
≤1 and re-start at a reduced dose according to Table 2.  Participants should be maintained at the 
reduced dose without attempt at dose re-escalation.  Participants experiencing Grade 4 diarrhea should 
be discontinued from study treatment. 
 
Erlotinib should not be restarted in those suspected of having drug-related interstitial lung disease (ILD). 
For any participants being taken off study due to a SAE, the issue will be reported as described in Section 
11.2.   
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
20 
 
Table 2.  Dosage Modification Criteria and Guidelines for Management  
of Erlotinib -Related Toxicities 
NCI-CTCAE  
(v 4.0) Grade 
Erlotinib Dose Modification 
Guideline for Management 
Diarrhea 
Grade 1 
None 
Consider loperamide (4 mg at first onset, 
followed by 2 mg q 2–4 hours until free 
of diarrhea for 12 hours) 
Grade 2 
None 
(Dose reduction of erlotinib is necessary if 
diarrhea persists over 48–72 hours despite 
optimal medical management) 
Loperamide (4 mg at first onset, followed 
by 2 mg q 2–4 hours until diarrhea free 
for 12 hours) 
Grade  3 
Interrupt then dose reduce erlotinib. 
Erlotinib should not be re-escalated. 
Interrupt erlotinib until resolution to 
Grade ≤1, and restart at next reduced 
dose 
Grade 4 
Discontinue study treatment. 
 
Pulmonary Events (if possibly ILD) 
All Grades 
Temporarily interrupt erlotinib pending the 
diagnostic evaluation.  If the pulmonary 
adverse event is assessed as related to 
erlotinib, discontinue the participant from 
study treatment. 
Unexplained dyspnea, either new or 
progressive, should be aggressively 
evaluated.   
Rash 
Grade 1 and 2 
and 
Tolerable rash 
None 
Any of the following: alcohol-free 
emollient cream, oral antibiotics 
(tetracycline, minocycline, doxycycline) 
topical clindamycin, diphenhydramine, 
topical or oral corticosteroids at 
discretion of investigator 
Grade 3 or 
Intolerable 
rash 
Consider interruption and or dose reduction 
if unresponsive to symptomatic 
management.  Re-escalation is allowed. 
Manage as described above 
Grade 4 
Discontinue study treatment. 
Manage as described above 
 
 
5.7 
Adherence/Compliance 
 
5.7.1 
Participant compliance with study visit and requirements will be documented.  Compliance with 
taking study medications will be documented via the use of medication diaries and recorded on case 
report forms for appropriate subgroup statistical analysis. 
 
5.7.2 
Participants will be required to complete and submit medication diaries.  Dispensed and 
returned medication will be accounted for according to DCP and Participating Organization policies and 
procedures.  
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
21 
 
 
6. 
PHARMACEUTICAL INFORMATION 
 
6.1 
Erlotinib (IND#: 64808, IND Sponsor: NCI, DCP)   
 
Clinical studies investigating the chemopreventive efficacy of erlotinib are conducted under IND 64808 
sponsored by NCI, DCP. Erlotinib (Tarceva®) is an epidermal growth factor receptor (EGFR) inhibitor 
approved by the FDA as a targeted therapy for the treatment of patients with locally advanced or 
metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletion or exon 21 
(L8568R) substitution mutation, after failure of at least one prior chemotherapy regimen. It is also 
indicated as first-line therapy for treatment of patients with locally advanced, unresectable, or 
metastatic pancreatic cancer in combination with gemcitabine. 
 
Erlotinib drug product is manufactured for OSI Pharmaceuticals, LLC by Astellas Pharma US (Northbrook, 
IL; Astellas). Erlotinib is currently formulated as conventional, immediate-release tablets in 25 mg, 100 
mg, and 150 mg strengths. For the purpose of this study, 25 and 150 mg strength tablets will be used. 
Erlotinib drug substance is an off-white to pale yellow powder. Conventional excipients in the 
formulation include lactose monohydrate, hypromellose, hydroxypropyl cellulose, microcrystalline 
cellulose, sodium starch glycolate, sodium lauryl sulfate, magnesium stearate, and titanium dioxide.  
 
6.2 
Reported Adverse Events and Potential Risks 
 
Safety evaluation of erlotinib is based on more than 1200 cancer patients who received erlotinib as a 
targeted therapy, more than 300 patients who received 100 or 150 mg erlotinib plus gemcitabine, and 
1228 patients who received erlotinib concurrently with other cancer treatments. The most common 
adverse reactions with erlotinib are rash and diarrhea usually with onset during the first month of 
treatment. The incidences of rash and diarrhea from clinical studies of erlotinib for the treatment of 
NSCLC and pancreatic cancer were 70% for rash and 42% for diarrhea.  
 
In first-line treatment of NSCLC patients with EGFR mutations, the most frequent (≥30%) adverse 
reactions in erlotinib-treated patients were diarrhea, asthenia, rash, cough, dyspnea, and decreased 
appetite.  Adverse events occurring in 4–20% of erlotinib-treated patients included pruritus, dry skin, 
and paronychia. The median time to onset of rash was 15 days and the median time to onset of diarrhea 
was 32 days. The most frequent grade 3/4 adverse reactions were rash and diarrhea. Dose interruptions 
or reductions due to adverse reactions occurred in 37% of erlotinib-treated patients, and 14.3% of 
erlotinib-treated patients discontinued therapy due to adverse reactions. In erlotinib-treated patients, 
the most frequently reported adverse reactions leading to dose modification were rash (13%), diarrhea 
(10%), and asthenia (3.6%). One erlotinib-treated patient experienced fatal hepatic failure and four 
additional patients experienced grade 3/4 liver test abnormalities in the first-line, randomized, open-
label clinical trial of erlotinib in NSCLC. 
 
As maintenance treatment in patients with locally advanced or metastatic NSCLC whose disease did not 
progress during first-line platinum-based chemotherapy, the most common adverse reactions in 
patients receiving single-agent 150 mg erlotinib were rash and diarrhea. Grade 3/4 rash and diarrhea 
occurred in 9% and 2%, respectively, in erlotinib-treated patients. Rash and diarrhea resulted in study 
discontinuation in 1% and 0.5% of erlotinib-treated patients, respectively, and dose reduction or 
interruption for rash and diarrhea was needed in 5% and 3% of patients, respectively. In erlotinib-

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
22 
 
treated patients the median time to onset of rash was 10 days, and the median time to onset of diarrhea 
was 15 days. Liver test abnormalities including alanine aminotransferase (ALT) elevations were observed 
at grade 2 or greater severity in 3% of erlotinib-treated patients and 1% of placebo-treated patients. 
Grade 2 and above bilirubin elevations were observed in 5% of erlotinib-treated patients and in <1% in 
the placebo group. 
 
In a study comparing first-line maintenance therapy with erlotinib administered at the time of disease 
progression in late-stage NSCLC, 11 deaths due to AEs occurred in patients who received erlotinib 
(pulmonary embolism [3 patients], pneumonia [2 patients], cardio-respiratory arrest, cardio-pulmonary 
failure, metabolic acidosis, cerebrovascular accident, hemoptysis, aspiration pneumonia) compared with 
3 patients who received placebo (lobar pneumonia, hydrocephalus, respiratory failure). 
 
In a study of erlotinib in second- and third-line treatment of NSCLC, the most common adverse reactions 
were also rash and diarrhea. Grade 3/4 rash and diarrhea occurred in 9% and 6%, respectively, in 
erlotinib-treated patients. Rash and diarrhea each resulted in study discontinuation in 1% of erlotinib–
treated patients, and 6% percent and 1% of patients needed dose reduction for rash and diarrhea, 
respectively. The median time to onset of rash was 8 days, and the median time to onset of diarrhea 
was 12 days. Liver function test abnormalities (including elevated ALT, aspartate aminotransferase 
[AST], and bilirubin) were observed in patients receiving single-agent erlotinib at 150 mg. These 
elevations were mainly transient or associated with liver metastases. Grade 2 (>2.5–5.0 × ULN) ALT 
elevations occurred in 4% and <1% of erlotinib and placebo treated patients, respectively. Grade 3 
(>5.0–20.0 × ULN) elevations were not observed in erlotinib-treated patients. 
 
The most common AEs in pancreatic cancer patients receiving 100 mg erlotinib plus gemcitabine were 
fatigue, rash, nausea, anorexia, and diarrhea; less common AEs included weight loss. In the 
erlotinib/gemcitabine arm, grade 3/4 rash and diarrhea were each reported in 5% of patients. The 
median time to onset of rash and diarrhea was 10 days and 15 days, respectively. Rash and diarrhea 
each resulted in dose reductions in 2% of patients and resulted in study discontinuation in up to 1% of 
patients receiving erlotinib/gemcitabine. The 150 mg cohort was associated with a higher rate of certain 
class-specific AEs, including rash, and required more frequent dose reduction or interruption. 
 
In the pancreatic carcinoma trial, 10 patients in the erlotinib/gemcitabine group developed deep venous 
thrombosis (incidence 3.9%), compared with three patients in the placebo/gemcitabine group (incidence 
1.2%). The overall incidence of grade 3 or 4 thrombotic events, including deep venous thrombosis, was 
similar in the two treatment arms: 11% for erlotinib/gemcitabine vs. 9% for placebo/gemcitabine. Liver 
function test abnormalities (including elevated ALT, AST, and bilirubin) were also observed. The 
erlotinib/gemcitabine treatment group had grade 2 (>2.5–5.0 × ULN) ALT elevations in 31% and grade 3 
(>5.0–20.0 × ULN) elevations in 13% compared with 22% for grade 2 and 9% for grade 3 in the 
placebo/gemcitabine group.  
 
There have been infrequent reports of serious interstitial lung disease (ILD)-like events, including 
fatalities, in patients receiving erlotinib for treatment of NSCLC, pancreatic cancer, or other advanced 
solid tumors. In the randomized single-agent NSCLC study the incidence of ILD-like events was the same 
in both the placebo and erlotinib groups (0.8%). In the pancreatic cancer study (in combination with 
gemcitabine), the incidence of ILD-like events was 2.5% in the erlotinib/gemcitabine group vs. 0.4% in 
the placebo/gemcitabine group. The overall incidence of ILD-like events in approximately 32,000 
erlotinib-treated patients from all studies (including uncontrolled studies and studies with concurrent 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
23 
 
chemotherapy) was approximately 1.1%. Reported diagnoses in patients suspected of having ILD-like 
events included pneumonitis, radiation pneumonitis, hypersensitivity pneumonitis, interstitial 
pneumonia, interstitial lung disease, obliterative bronchiolitis, pulmonary fibrosis, acute respiratory 
distress syndrome, and lung infiltration. Symptoms started from five days to more than nine months 
(median 39 days) after initiating erlotinib therapy. In the lung cancer trials, most of the cases were 
associated with confounding or contributing factors such as concomitant/prior chemotherapy, prior 
radiotherapy, pre-existing parenchymal lung disease, metastatic lung disease, or pulmonary infections. 
 
Cases of hepatorenal syndrome, acute renal failure (including fatalities), or renal insufficiency with or 
without hypokalemia have been reported. Some were secondary to severe dehydration due to diarrhea, 
vomiting, and/or anorexia while others were confounded by concurrent chemotherapy use.  
 
Asymptomatic increases in liver transaminases have been observed in erlotinib-treated patients. Rare 
cases of hepatic failure (including fatalities) have been reported during postmarketing use of erlotinib. 
Confounding factors for severe hepatic dysfunction have included pre-existing liver disease or 
concomitant treatment with potentially hepatotoxic drugs. The pooled incidence of hepatic failure in the 
three monotherapy lung cancer studies, where patients with moderate to severe hepatic impairment 
were excluded, was 0.4% in the erlotinib arms and 0% in the control arms. The incidence of hepatic 
failure in the pancreatic cancer study was 0.4% in the erlotinib plus gemcitabine arm and 0.4% in the 
control arm. 
 
During NSCLC and combination pancreatic cancer trials, infrequent cases of gastrointestinal bleeding 
have been reported, some associated with concomitant warfarin or NSAID administration. These AEs 
were reported as peptic ulcer bleeding (gastritis, gastroduodenal ulcers), hematemesis, hematochezia, 
melena, and hemorrhage from possible colitis. Gastrointestinal perforation, including fatal cases, have 
been rarely reported with erlotinib treatment. Patients receiving concomitant anti-angiogenic agents, 
corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration 
or diverticular disease may be at increased risk of perforation. The pooled incidence of gastrointestinal 
perforation in the three monotherapy lung cancer studies was 0.2% in the erlotinib arms and 0.1% in the 
control arms. The incidence of gastrointestinal perforation in the pancreatic cancer study was 0.4% in 
the erlotinib plus gemcitabine arm and 0% in the control arm. 
 
Corneal ulcerations or perforations have been reported in patients receiving erlotinib. Decreased tear 
production, abnormal eyelash growth, keratoconjunctivitis sicca, and keratitis have been reported and 
are risk factors for corneal ulceration/perforation.   Hair and nail changes, mostly non-serious, were 
reported; paronychia was reported commonly and hirsutism, eyelash/eyebrow changes, and brittle and 
loose nails were reported uncommonly.  Bullous, blistering, and exfoliative skin conditions, including 
cases suggestive of Stevens-Johnson syndrome/toxic epidermal necrolysis, which in some cases were 
fatal, can occur with erlotinib treatment. The pooled incidence of bullous and exfoliative skin disorders 
in the three monotherapy lung cancer studies was 1.2% in the erlotinib arms and 0% in the control arms. 
The incidence of bullous and exfoliative skin disorders in the pancreatic cancer study was 0.4% in the 
erlotinib plus gemcitabine arm and 0% in the control arm. 
 
In the pancreatic carcinoma trial, six patients (incidence 2.1%) in the erlotinib/gemcitabine group 
developed myocardial infarction/ischemia. One of these patients died due to myocardial infarction. In 
comparison, three patients in the placebo/gemcitabine group developed myocardial infarction 
(incidence 1.1%) and one died due to myocardial infarction. In the same trial, seven patients in the 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
24 
 
erlotinib/gemcitabine group developed cerebrovascular accidents (incidence 2.5%). One of these was 
hemorrhagic and was the only fatal event. In contrast, there were no cerebrovascular accidents in the 
placebo/gemcitabine group. The pooled incidence of microangiopathic hemolytic anemia with 
thrombocytopenia in the three monotherapy lung cancer studies was 0% in the erlotinib arms and 0.1% 
in the control arms. The incidence of microangiopathic hemolytic anemia with thrombocytopenia in the 
pancreatic cancer study was 1.4% in the erlotinib plus gemcitabine arm and 0% in the control arm. Other 
mild skin reactions, such as hyperpigmentation, have been observed uncommonly (in <1% of patients). 
 
In the previously reported FAPEST study, 83% of participants experienced Grades 1-3 adverse events. 
There were no Grade 4 or 5 events. The most common adverse event was an erlotinib-induced 
acneiform-like rash, which occurred in 87% of the treatment group (n=40) and 20% of the placebo group 
(n=9) (P < .001). The rash was managed with topical cortisone and/or clindamycin therapy. Additional 
adverse events commonly increased in the treatment group included oral mucositis (39.1%; n=18), 
diarrhea (26%; n=12), and nausea (23.9%; n=11).  Of the participants who completed the study, 73% had 
erlotinib dose reductions due to grade 1 and 2 rash that were deemed intolerable by the participants.20 
 
Erlotinib can cause fetal harm when administered to a pregnant woman; therefore, women should avoid 
becoming pregnant while being treated with erlotinib. Adequate contraceptive methods should be used 
during therapy and for at least two weeks after discontinuing erlotinib. There are no adequate and well-
controlled studies in pregnant women using erlotinib; however, studies in animals have shown some 
reproductive toxicity. Breastfeeding should be discontinued while taking erlotinib. While it is not known 
whether erlotinib is excreted in human milk, erlotinib and/or its metabolites were excreted in milk in 
animals.  
 
Erlotinib is protein bound (92–95%) in humans and metabolized in the liver by cytochrome P450 
(CYP)3A4, and to a lesser extent CYP1A2, and in the lungs by CYP1A1. A potential for drug-drug 
interaction exists when erlotinib is coadministered with drugs that are highly protein bound or that are 
potent CYP3A4 inhibitors/inducers. Potent inducers of CYP3A4 activity increase erlotinib metabolism 
and significantly decrease erlotinib plasma concentrations, while potent CYP3A4 inhibitors increase 
exposure to erlotinib. For patients who are being concomitantly treated with a potent CYP3A4 inhibitor, 
a dose reduction should be considered in the presence of severe AEs. For patients who are being 
concomitantly treated with a potent CYP3A4 inducer, alternative treatments that lack potent CYP3A4-
inducing properties should be considered. Potent CYP3A4 inhibitors include ketoconazole, atazanavir, 
clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, 
troleandomycin, voriconazole, and grapefruit or grapefruit juice. CYP3A4 inducers include rifampicin, 
rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, and St. John's Wort. 
 
Cigarette smoking has been shown to reduce erlotinib exposure; therefore, smokers should be advised 
to stop smoking while taking erlotinib. 
 
Drugs that alter the pH of the upper GI tract may alter the solubility of erlotinib and reduce its 
bioavailability. Coadministration of erlotinib with omeprazole, a proton pump inhibitor, decreased the 
erlotinib exposure and maximum concentration by 46% and 61%, respectively; therefore, the 
concomitant use of proton pump inhibitors with erlotinib should be avoided. 
 
Altered coagulation parameters and infrequent reports of bleeding events, including gastrointestinal 
and non-gastrointestinal bleeding, have been reported in patients in erlotinib clinical studies, some 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
25 
 
associated with concomitant warfarin administration. Patients taking warfarin or other coumarin-
derivative anticoagulants will be excluded. 
 
6.3  
Availability 
 
Erlotinib will be obtained from Astellas by NCI, DCP for use in this study.  Erlotinib will be handled and 
distributed by the NCI, DCP repository contractor MRI Global (Kansas City, MO).   
 
6.4 
Agent Distribution 
 
Agents will only be released by NCI, DCP after documentation of IRB approval of the DCP-approved 
protocol and consent is provided to DCP and the collection of all Essential Documents is complete (see 
DCP website for description of Essential Documents).  
 
NCI, DCP-supplied agents may be requested by the Investigator (or their authorized designees) at each 
Organization. DCP guidelines require that the agent be shipped directly to the institution or site where 
the agent will be prepared and administered. DCP does not permit the transfer of agents between 
institutions (unless prior approval from DCP is obtained). DCP does not automatically ship agents; the 
site must make a request. Agents are requested by completing the DCP Clinical Drug Request form (NIH-
986) (to include complete shipping contact information) and faxing or mailing the form to the DCP agent 
repository contractor: 
 
John Cookinham, MRIGlobal, DCP Chemoprevention Agent Repository 
1222 Ozark Street, North Kansas City, MO  64116   
Phone: 816-360-3805 
FAX:  816-753-5359 
Email: NCI.DCP@mriglobal.org 
Emergency telephone: 816-360-3800 
 
6.5  
Agent Accountability 
 
The Investigator, or a responsible party designated by the Investigator, must maintain a careful record of 
the inventory and disposition of all agents received from DCP using the NCI Drug Accountability Record 
Form (DARF). The Investigator is required to maintain adequate records of receipt, dispensing and final 
disposition of study agent. This responsibility has been delegated to each sites’ licensed pharmacy staff 
as listed on the site-specific Delegation of Tasks document. Include on receipt record from whom the 
agent was received and to whom study agent was shipped, date, quantity and batch or lot number. On 
dispensing record, note quantities and dates study agent was dispensed to and returned by each 
participant.  
 
6.6 
Packaging and Labeling 
 
Erlotinib is packaged in high density polyethylene bottles, each containing thirty (30) tablets. Erlotinib 
will be supplied in two bottles, one containing thirty (30) 150mg tablets and one containing thirty (30) 
25mg tablets, and will be labeled with the following content: product identification and strength, NSC 
number, tablet count, lot/batch number, expiration date, name and address of manufacturer, storage 
information, investigational use language (Caution: New Drug Limited by Federal Law to Investigational 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
26 
 
Use Only. Keep out of reach of children”), and instructions to take as directed. Prior to dispensing 
investigational product, trial personnel will attach a label containing the participant identification 
number, randomization number, and dispensing date.  
 
6.7 
Storage 
 
Erlotinib tablets (150 mg and 25 mg) are supplied in high density, polyethylene bottles and should be 
stored in a secure location.  Storage will be maintained at 25° C (77°F); excursions permitted to 15°C - 
30°C (59°F - 86°F).  See USP Controlled Room Temperature. 
 
6.8 
Pre-Registration and Registration 
 
6.8.1 Participant Pre-Registration 
 
6.8.1.1 To pre-register a participant, the participating site will fax or email the completed Pre-
Registration Eligibility Checklist to the CPN Registration Office (Fax: 507-284-0885; Email:  
Random01@mayo.edu). The CPN Registration Office will enter the data into the CPN-hosted database. 
 
6.8.1.2 At the time of pre-registration, the following will be verified: 
• 
CIRB approval (local context subcommittee) and IRB acknowledgement of CIRB approval and 
informed consent at the registering institution 
• 
Participant eligibility (including existence of a signed informed consent document) 
• 
Existence of a signed authorization for use and disclosure of protected health information (USA 
Institutions only). 
• 
Study agent is available and Drug Shipment Authorization has been granted to the registering 
site.     
 
The following will also be recorded: 
• 
Participant has/has not given permission to collect and store blood, urine, and/or tissue 
specimens and related information in a Biobank for future use in research to learn about, 
prevent, treat, or cure cancer and other health problems. 
• 
Participant has/has not given permission to contact him/her or his/her physician to learn about 
the results of these studies. 
• 
Participant has/has not given permission to send blood, urine, and/or tissue specimens and 
related information to researchers at outside institutions. 
• 
Participant has/has not given permission for information from the alcohol and tobacco use 
assessment to be used in future health research. 
• 
Participant has/has not given permission to his/her doctor or their representative to ask them if 
they wish to participate in other research in the future. 
6.8.1.3   Baseline (screening) evaluations must be completed within the guidelines specified on the 
Schedule of Events (See Section 7.1). 
 
6.8.1.4 Registration Office personnel will automatically register participants separately to the 
translational components of the study (See Section 13). 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
27 
 
6.8.2 Registration 
 
 
6.8.2.1 To register a participant, the participating site will fax or email the completed Registration 
Eligibility Checklist to the CPN Registration Office (Fax: 507-284-0885; Email:  Random01@mayo.edu) to 
register all participants. The CPN Registration Office will enter the data into the CPN-hosted database. 
 
6.8.2.2 Intervention cannot begin prior to registration and must begin ≤ 14 days from registration. 
 
6.8.2.3 Intervention must take place at a CPN institution and under the supervision of a CPN clinician. 
 
6.8.2.4 Pathology reports confirming diagnoses must be uploaded into the database via Medidata Rave 
≤ 30 days post Registration.  
 
6.8.2.5   Descriptive Factors collected at baseline:   
• 
Participating Site 
• 
Classic or attenuated FAP 
• 
Baseline aspirin use 
• 
Severity of duodenal polyposis (Spigelman stage 2 versus 3). 
 
After the participant has been registered on to the study, values of the descriptive factors will be 
recorded.   
 
6.9 
Blinding and Unblinding Methods 
 
Not applicable 
 
6.10 
Agent Destruction/Disposal 
 
Per the agreement between NCI, DCP and Astellas Pharma for the supply of erlotinib, returned, unused, 
or undispensed study agent is to be returned to MRIGlobal.    
 
Institutions that have policies requiring the immediate destruction of returned/unused erlotinib may do 
so under the following conditions: The site’s process for destruction of patient returns should include 
documentation of the destruction that includes lot numbers and quantities. This documentation should 
then be provided to MRIGlobal (NCI.DCP@mriglobal.org). MRIGlobal will use the information to 
reconcile inventory.   
 
At the completion of the study or upon expiration of the shelf supply, any undispensed study agent will 
be returned to MRIGlobal.  They will reconcile and request permission for destruction from Astellas, per 
their requested procedure.  Please following DCP Guidelines for agent returns and use the agent return 
from the DCP website. 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
28 
 
7. 
CLINICAL EVALUATIONS AND PROCEDURES 
 
7.1 
Schedule of Events 
 
Evaluation/ 
Procedure 
Pre-
Registration1 
Screening/ 
Baseline1 
Registration 
Month 1  
(+/- 4 days) 
Months  
2, 4, 5  
(+/- 7 days) 
Month 3  
(+/- 7 days) 
Month 6 or 
Early 
Termination 
(+/- 10 days) 
Follow-Up – 
Month 7 
(+/- 10 
days) 
Informed Consent 
X 
 
 
 
 
 
 
 
Assess Eligibility 
 
X 
 
 
 
 
 
 
Medical/Surgical 
History 
 
X 
 
 
 
 
 
 
Physical Exam 
with vital signs  
(Ht, Wt, temp, 
pulse, BP) 
 
X 
 
X 
 
X 
X 
 
Alcohol and 
tobacco use 
assessments 
 
X 
 
 
 
 
X 
 
Clinical Laboratory 
Tests2 
 
X 
 
X 
 
X 
X3 
X3 
Urinalysis and 
urine cotinine6 
 
X 
 
X 
 
X 
X 
 
EGD/lower GI 
endoscopy with 
biopsies and 
tattooing 
 
X7 
 
 
 
 
X7 
 
Submission of CT 
imaging and 
report 
 
X4 
 
 
 
 
X4 
 
Research blood 
and urine 
collection 
 
X 
 
 
 
X 
X 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
29 
 
Evaluation/ 
Procedure 
Pre-
Registration1 
Screening/ 
Baseline1 
Registration 
Month 1  
(+/- 4 days) 
Months  
2, 4, 5  
(+/- 7 days) 
Month 3  
(+/- 7 days) 
Month 6 or 
Early 
Termination 
(+/- 10 days) 
Follow-Up – 
Month 7 
(+/- 10 
days) 
Pregnancy test, 
serum or urine, if 
applicable5 
 
X 
X 
 
 
X 
X 
 
Concomitant 
Medications 
 
X 
 
X 
X 
X 
X 
X 
Dispense Study 
Agent  and 
Medication Diaries 
 
 
X 
 
 
X 
 
 
Collect/Review 
Study Agent and 
Medication Diaries 
 
 
 
 
 
X 
X 
 
Was It Worth It 
(WIWI) 
 
 
 
 
 
 
X 
 
Adverse Events 
 
 
X 
X 
X 
X 
X 
X 
Telephone 
Contact 
 
 
 
 
X 
 
 
X 
 
1. Pre-Registration and screening must take place ≤ 45 days prior to registration. 
2. Clinical safety and toxicity laboratory testing includes CBC (with 5-part differential, platelets, and hemoglobin), Albumin, Bilirubin (Total), Calcium, 
Carbon dioxide (Bicarbonate), Chloride, Creatinine, Glucose, Alkaline phosphatase, Potassium, Protein (Total), Sodium, ALT/SGPT, AST/SGOT, and 
Blood Urea Nitrogen (BUN). 
3. If any test results are outside of institutional limits of normal and clinically-significant, they will be repeated at Month 7.  
4. For individuals with desmoid tumors who have CT imaging at least twice yearly as part of their standard clinical care/surveillance, CT images and local 
radiologists’ reports will be submitted for central review ≤ 30 days from registration and ≤ 30 days after Month 6 
5. A negative serum or urine pregnancy test (WOCBP only) must be documented ≤ 7 days prior to registration.  If screening pregnancy test took place ≤ 7 
days prior to registration, it does not have to be repeated. 
6. Urine cotinine will be tested at baseline and Month 6/early termination only. 
7. The lower GI endoscopy is preferred but it is optional. It should be performed only if clinically-indicated.    

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
30 
 
7.2 
Baseline Testing/Prestudy Evaluation 
 
Potentially eligible participants will undergo an educational session explaining the study, major 
endpoints, and potential risks. Based on the pre-registration inclusion and exclusion criteria (See 
Sections 4.1 and 4.2), participants will be determined to be potentially eligible for this trial. After 
appropriate discussions, written informed consent will be obtained.  Results of clinically-indicated 
genetic analysis to confirm presence or absence of the APC mutation will be recorded, if available. 
Following informed consent, participants will be pre-registered to the study.   
 
Screening will include a physical exam with vital signs, review of medical/surgical history, review of 
baseline symptoms and concomitant medications, alcohol and tobacco use assessments, clinical 
laboratory tests (CBC [with 5-part differential, platelets, and hemoglobin], Albumin, Bilirubin [Total], 
Calcium, Carbon dioxide [Bicarbonate], Chloride, Creatinine, Glucose, Alkaline phosphatase, Potassium, 
Protein [Total], Sodium, ALT/SGPT, AST/SGOT, and Blood Urea Nitrogen [BUN]), urinalysis and urine 
cotinine, and research blood and urine collection. A pregnancy test will be administered, if applicable. 
 
If still eligible and willing, participants will undergo an esophagogastroduodenoscopy (EGD) plus lower 
GI endoscopy with biopsies and tattooing.  The lower GI endoscopy is preferred but optional (See 
Section 7.6 for details). 
 
For individuals with desmoid tumors who have CT imaging at least twice yearly as part of their standard 
clinical care, CT images along with the local radiologist’s report from before and after intervention will 
be submitted for central review. 
 
Screening must be completed ≤ 45 days prior to registration.  After registration, participants will be 
dispensed a 3-month supply of study agent (See Section 5.2), a medication and symptom diary, and 
appropriate instructions. 
 
7.3 
Evaluation During Study Intervention 
 
At Month 1 (+/-4 days), a visit will take place including physical exam with review of vital signs, review of 
adverse events and concomitant medications, clinical laboratory tests (CBC [with 5-part differential, 
platelets, and hemoglobin], Albumin, Bilirubin [Total], Calcium, Carbon dioxide [Bicarbonate], Chloride, 
Creatinine, Glucose, Alkaline phosphatase, Potassium, Protein [Total], Sodium, ALT/SGPT, AST/SGOT, 
and Blood Urea Nitrogen [BUN]), and urinalysis.  The medication and symptom diaries will be reviewed 
to confirm participant understanding of the instructions, but they will not be collected. 
 
Participants will be contacted by phone at Months 2, 4, and 5 (+/-7 days) to review adverse events and 
concomitant medications. 
 
At Month 3 (+/-7 days), a visit will take place including physical exam with review of vital signs, review of 
adverse events and concomitant medications, clinical laboratory tests (CBC [with 5-part differential, 
platelets, and hemoglobin], Albumin, Bilirubin [Total], Calcium, Carbon dioxide [Bicarbonate], Chloride, 
Creatinine, Glucose, Alkaline phosphatase, Potassium, Protein [Total], Sodium, ALT/SGPT, AST/SGOT, 
and Blood Urea Nitrogen [BUN]), and urinalysis. Research blood and urine will be collected. A pregnancy 
test will be performed, if applicable. Any unused agent will be collected and a new supply (as described 
in Section 5.2) dispensed.  Medication and symptoms diaries will be collected and new ones provided. 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
31 
 
7.4 
Evaluation at Completion of Study Intervention 
 
At Month 6 (+/-10 days), a post-intervention visit will take place, including physical exam with review of 
vital signs, review of adverse events and concomitant medications, follow-up alcohol and tobacco use 
assessments, clinical laboratory tests (CBC [with 5-part differential, platelets, and hemoglobin], Albumin, 
Bilirubin [Total], Calcium, Carbon dioxide [Bicarbonate], Chloride, Creatinine, Glucose, Alkaline 
phosphatase, Potassium, Protein [Total], Sodium, ALT/SGPT, AST/SGOT, and Blood Urea Nitrogen 
[BUN]), urinalysis and urine cotinine, and research blood and urine collection. A pregnancy test will be 
performed, if applicable. Any unused agent and all medication/symptom diaries will be collected. 
Participants will undergo an EGD plus lower GI endoscopy with clearing of all polyps, according to 
institutional standards of care, plus research biopsies.  All efforts should be made to confirm the same 
endoscopist performs the pre- and post-intervention endoscopy procedures. 
 
7.5 
Post-intervention Follow-up Period 
Participants should be seen in the clinic or contacted by telephone to determine if any serious or non-
serious adverse events have occurred within 30 days (±7 days) of termination of study participation, 
whether they complete the 6-month trial or not.  If abnormal and clinically-significant laboratory values 
are found at the end of the study, these will be repeated at this time point.  If all lab values are normal 
at Month 6, no additional laboratory tests will be done.  
End-of-Treatment Evaluations due to early withdrawal 
 
If a participant discontinues use of the study medication prior to 6-month trial completion, the following 
will be performed:   
a. Reason for discontinuation will be determined and recorded in participant’s file. 
b. Clinic visit for history and physical exam, and EGD and lower GI endoscopy (if intact 
colon or rectal stump).   
c. Management of adverse events according to institutional standards of good clinical 
practice and notification of NCI, DCP medical monitor 
d. Review of concomitant medications, compliance assessment, and return of unused 
study agent  
e. All blood tests and urinalysis/urine cotinine will be performed.  Research blood and 
urine collection will be performed if consent provided. 
 
7.6 
Methods for Clinical Procedures 
 
Endoscopic Screening: Participants will be monitored per institutional standards of good clinical practice 
(i.e. blood pressure, heart rate, pulse oxygenation) and then appropriately sedated.  The examination 
and measurement components of the endoscopy procedures will be implemented in a manner 
consistent with the FAPEST study, recently reported in JAMA,20 as outlined in brief below. 
 
Upper GI Endoscopy: The duodenum will be evaluated by forward-viewing and/or side-viewing 
gastroscopes (with still and video documentation). Esophagogastroduodenoscopy (EGD) will be 
performed and a tattoo placed 10 cm distal to the duodenal bulb to define a region heretofore referred 
to as the duodenal segment, which will extend from the duodenal bulb distally to the tattoo. Endoscopic 
tattooing has been widely employed in previous research protocols and is clinically used by many 
authorities.25, 26 Intramucosal injections of 0.5 ml to 2 ml are used as necessary to mark the mucosa.  All 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
32 
 
participants will have screening/baseline and final study endpoint (Month 6) UGI endoscopy as part of 
this trial. 
 
Lower GI Endoscopy (preferred but optional): Willing participants will be evaluated via flexible 
proctosigmoidoscopy during the screening/baseline examination and final study endpoint (Month 6) 
evaluation. Flexible sigmoidoscopy will be used to examine the pouch, rectum (IRA), or rectal stump 
(IPAA) in FAP or attenuated FAP individuals who have undergone colectomy.  For consistency, those 
with a rectum or rectal stump, biopsies of normal tissue will only be done if 10 cm of rectum (from the 
anal verge) is present. 
 
Video Recording and capture of still images:  All procedures will be recorded in high definition using 
Medicapture (or comparable) records to allow for blinded physician review as a secondary endpoint.  
Still images are highly recommended but not required.  Still images (photos) should be taken at baseline 
and Month 6 in the center of the lumen at 1 cm increments during withdrawal from the duodenum.  Any 
large polyps, particularly those that are biopsied for Spigelman staging at baseline, should also be 
photographed with the biopsy forceps visible to provide a reference for size. 
 
Pre-treatment Endoscopic Assessment. Topical lidocaine will be used for pharyngeal anesthesia. 
Conscious sedation will be administered by the endoscopist-investigator, as is the current clinical 
standard of practice.  Medicines will primarily consist of midazolam and fentanyl, but other sedatives 
are occasionally needed.  Endoscopy will be performed in the standard fashion.  A side-viewing 
endoscope (preferred) will be used specifically to examine and record the size of the ampulla of Vater in 
the duodenum.  If this cannot be done, then viewing with the forward viewing endoscope is acceptable.  
Biopsies of the ampulla of Vater will only be obtained if it appears abnormally large or suspicious for 
malignancy.  The size, location, and number of polyps will be determined and recorded, consistent with 
procedures that have been used extensively in polyp studies. Each polyp in the duodenal segment will 
be measured, mapped, and recorded at 1-cm intervals in the 10-cm segment.  In the rectum, each polyp 
will be measured and recorded. 
 
Counting and mapping polyps will be performed prior to collection of any biopsies or removal of any 
polyps. 
 
At baseline, at least one polyp will be biopsied and sent for local histological analysis for eligibility 
determination and Spigelman stage determination.  This specimen will be collected and processed 
according to institutional standard operating procedures.  Any lesions containing high-grade dysplasia or 
cancer will result in a referral to surgery and oncology, and, exclusion of the patient from the study.  Any 
lesions that are ≥ 10mm and/or worrisome for high grade dysplasia or cancer in the opinion of the 
endoscopist, should be removed or sampled according to institution standards of care. This should be 
noted on the endoscopy report. Participants with extensive, but quantifiable, duodenal polyposis will 
not be necessarily excluded from the study unless histological analysis reveals high grade dysplasia or 
cancer.  These specimens are not among the specimens being collected for research purposes. 
 
For research purposes, four endoscopic biopsies of grossly normal duodenal mucosa and one (for 
Spigelman 2) or two (Spigelman 3) endoscopic biops(ies) of duodenal polyp will be obtained from all 
participants at screening/baseline and end of the study (Month 6).  One biopsy from both normal and 
polyp at each time point will be placed in RNA later, and the remaining specimens will be snap frozen in 
liquid nitrogen.  Note:  if Spigelman Stage is not known at the time of the baseline endoscopy, the 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
33 
 
endoscopists should use their best clinical judgement regarding Spigelman 2 versus Spigelman 3 based 
on the size and number of polyps.  If the subsequent pathology assessment differs from the 
endoscopist’s assessment, a note-to-file will be created for the participant’s file. 
 
Polyps on the ampula of Vater should be included in the mapping and counting process. These polyps 
should be biopsied if worrisome. 
 
At Month 6, the side-viewing endoscope (preferred) will be used specifically to examine and record the 
size of the ampulla of Vater in the duodenum.  If this cannot be done, then viewing with the forward 
viewing endoscope is acceptable.   
 
If there are at least 10 cm of rectum, four endoscopic biopsies of normal rectal mucosa will be obtained 
in patients with a rectal stump or intact rectum at screening/baseline and end of the study (Month 6).  
One biopsy of rectal mucosa at each time point will be placed in RNA later, and the remaining specimens 
will be flash frozen in liquid nitrogen. 
 
For individuals with desmoid tumors who have surveillance CT (with contrast) imaging at least twice 
yearly as part of their standard clinical care, CT images along with the local radiologist’s report will be 
submitted for central radiology review, which will take place at the University of Utah.  The radiology 
reviewer (MEH) will be blinded as to the time point (pre-intervention versus post-intervention) and 
enrolling institution.   
 
8.  
CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION 
 
8.1 
Primary Endpoints 
 
• 
Polyp Burden:   To assess the mean percent change in duodenal polyp burden (sum of diameters 
from all polyps) from baseline to 6 months post-intervention as assessed by 
esophagogastroduodenoscopy (EGD) for FAP subjects receiving weekly erlotinib.  The hypothesis 
is that weekly erlotinib will significantly reduce duodenal polyp burden after 6 months of 
treatment.   
• 
Adverse events (if polyp burden shows a significant decrease from baseline):  To assess the 
grade 2/3 adverse event rate in this population and compare it to historical data.  The 
hypothesis is that weekly erlotinib will significantly reduce the grade 2/3 AE rate compared to 
historical control data.  
 
8.2      Secondary Endpoints 
 
• 
To evaluate all adverse events associated with the weekly erlotinib; 
• 
To assess the absolute and percent change in duodenal polyp number from baseline to 6 
months;   
• 
To assess the absolute and percent changes in lower gastrointestinal polyp burden and number 
for the subset of participants with ileal pouch anal anastomosis (IPAA) or ileo-rectal anastomosis 
with rectal stump (anticipated to be approximately 70% of registered cohort); and 
• 
To assess the absolute and percent change in desmoid tumor size in participants who have 
baseline and follow up CTs performed as part of their standard of care (anticipated to be 
approximately 30% of the registered cohort); 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
34 
 
• 
Gene expression profiles in duodenal adenomas and uninvolved tissue will be compared 
between baseline and endpoint samples using negative binomial statistics (DESeq2): 
o Identify differentially expressed genes between duodenal polyps and uninvolved tissue 
at endpoint compared to baseline; 
o 
Evaluate the effect of weekly erlotinib on EGFR and Wnt target gene expression in 
duodenal adenomas 
o 
Evaluate the effect of weekly erlotinib on immune response signaling in duodenal 
adenomas and uninvolved tissue.  Global gene expression (RNA transcriptome) will be 
measured by RNA sequencing. This global RNA analysis includes all immune response 
genes. These analyses will be done by Dr. Don Decker, Huntsman Cancer Institute, 
University of Utah. 
 
8.3 
Off-Agent Criteria  
 
Participants may stop taking the study agent due to: completion of the planned intervention period, 
development of an adverse event or serious adverse event, inadequate agent supply, noncompliance, 
use of concomitant medications, medical contraindication, refusal, ineligibility (see Section 8.4), major 
treatment violation (see Section 8.4) or alternative treatment. Participants will continue to be followed, 
if possible, for safety according to the intended schedule of events (see Section 7).  
 
Participants discontinuing the planned intervention prematurely will be encouraged to complete the 
Post-Intervention Evaluation tests and procedures as described below (if participant does not refuse, is 
not lost to follow-up, or unless it is clinically contraindicated).  
 
If a participant discontinues study agent before Month 3 due to adverse events, it is preferable to 
continue AE assessment through Month 7.  This can be done by phone, if preferred.  Endoscopies and 
blood testing do not need to be performed unless clinically indicated.   
 
If the participant discontinues study agent after the Month 3 time point, perform the Month 6 visit, 
including endoscopy, within 10 days of discontinuing agent.  If it cannot be done within 10 days, 
schedule the visit and procedures as close as possible to this time point.   
 
See Section 8.4 for further details as to data submission for participants deemed Ineligible after starting 
treatment or classified as a Major Treatment Violation (i.e., protocol requirements regarding 
intervention during the first week post-registration were severely violated). 
 
8.4 
Off-Study Criteria 
 
Participants may go “Off-Study” for the following reasons: development of an adverse event or serious 
adverse event, death, lost to follow-up, participant withdrawal, physician decision, protocol violation, 
complete study, or other (with detailed comments provided). Reason(s) will be noted in the participant’s 
research records, with the primary reason clearly identified. The participant will be classified as (Off 
Study/Off Agent). Data submission and follow-up after participants are determined to be “Off-Study/Off-
Agent” for specific situations is noted below: 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
35 
 
A registered participant is deemed ineligible if the participant did not satisfy each and every eligibility 
criterion at the time of study entry, for example, identified based on an audit or through the case 
evaluation process. 
 
• 
If participants received study intervention, on-study materials and all data up until the 
point of confirmation of ineligibility will be submitted. 
• 
If participants did not receive study intervention, on-study materials must be submitted. No 
further data submission is necessary. No follow-up is required. 
 
Major Treatment Violation: A registered participant is deemed as being in major treatment violation by 
the coordinating center, if the participant’s very first treatment/intervention administration is so grossly 
administered in error, that the participant’s data can no longer be used for the primary endpoint. These 
cases are typically rare. 
 
• 
On-study material and all data up until the point of confirmation of a major violation must be 
submitted. 
 
Cancel/Participant Withdrawal: A registered participant is deemed a cancel if he/she refuses the study 
or withdraws consent before any study intervention is given.  On-study material must be submitted. The 
Off Study case report form must be submitted.    No follow-up is required. 
 
8.5 
Study Termination 
 
NCI, DCP as the study sponsor has the right to discontinue the study at any time.  
 
9. 
CORRELATIVE/SPECIAL STUDIES 
 
9.1 
Rationale for Methodology Selection 
 
See Biomarker Methods Development Report. 
 
9.2 
Comparable Methods 
 
Methodology for this study is consistent with the FAPEST trial,20 which should result in data that can be 
compared to existing data. 
 
10. 
SPECIMEN MANAGEMENT  
 
10.1 
Laboratories 
 
Clinical laboratory evaluations will take place at each institution’s clinical laboratories as listed on the 
study-specific FDA form 1572.  These include blood chemistry, hematology, and urinalyses. 
 
RNA extractions and RNA sequencing: 
Don A. Delker, Ph.D., Laboratory Manager 
Division of Gastroenterology, Hepatology and Nutrition 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
36 
 
School of Medicine, University of Utah 
30 North 1900 East, Salt Lake City, UT 84132 
Phone: 801-585-0328 
Email: don.delker@hsc.utah.edu 
 
10.2 
Collection and Handling Procedures 
 
 
Research blood kits for shipping blood, urine, and tissue for all research analyses will be provided by BAP 
Kit Building (Biospecimen Accessioning and Processing Core Facility).  Detailed collection, handling, and 
shipping instructions will be included with each kit.  Participating Sites may obtain research kits by faxing 
the BAP Kit Supply Order Form to the number provided (found in the Forms Packet).  At least two weeks 
should be allowed to receive the shipping kits.  Kits will be sent via FedEx® Ground at no additional cost 
to the participating institutions.  They will not be forwarded by FedEx® rush delivery service unless the 
participating institution provides their own FedEx® account number.  CPN will not cover the cost for rush 
delivery of kits. Because charges are incurred for all outgoing kits, a small, but sufficient, supply of 
specimen collection kits should be ordered prior to participant entry. 
 
• 
All sections of the requisition form, specimen submission CRFs, and specimen collection labels 
must be completed and legible.  
• 
Specimens should be sent overnight via FedEx® on dry ice.  All specimens must be shipped to 
the address provided on the specimen shippers.   
• 
All specimens will be shipped in compliance with the International Air Transport Association 
(IATA) Dangerous Goods Regulations. 
 
10.2.1 Clinical Blood and Urine Specimens 
 
Clinical blood and urine specimens will be collected and processed according to each institution’s 
internal standard operating procedures.  Results will be reported on the appropriate case report forms. 
 
10.2.2 Research Blood and Urine Specimens 
 
Using the required BAP kits, an optional blood specimen (one 10 mL no additive red-topped tube, and 
one 10 mL purple topped tube) will be collected at screening/baseline and end of study (Month 6), 
processed into serum, plasma, and buffy coat, frozen, and shipped to BAP (see below) for storage for 
future research.   
 
An optional urine specimen will also be collected, frozen, and shipped on dry ice, overnight to the BAP 
freezer. 
 
Specimens will be frozen at -20o or colder and shipped on dry ice, M-F, overnight to the BAP Freezer: 
 
Biospecimens Accessioning and Processing (BAP) Freezer 
ST SL-16, 150 Third Street Southwest, Rochester, MN  55902 
 
 
 
Questions should be addressed to: 
 
 
Roxann Neumann, Biospecimens Resource Manager 
Phone: 507-538-0602; Email: Neumann.roxann@mayo.edu 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
37 
 
10.2.3 Tissue Specimen Collection and Submission 
 
At baseline, at least one polyp will be removed and sent for local histological analysis for eligibility 
determination and Spigelman stage determination (See Section 7.6).  This specimen will be collected and 
processed according to institutional standard operating procedures. 
 
Four endoscopic biopsies of normal duodenal mucosa and one (for Spigelman 2) or two (Spigelman 3) 
endoscopic biops(ies) of duodenal polyp will be obtained from all participants at screening/baseline and 
end of the study (Month 6).  One biopsy from both normal and polyp at each time point will be placed in 
RNA later, and the remaining specimens will be snap frozen in liquid nitrogen. 
 
Four endoscopic biopsies of normal rectal mucosa will be obtained in patients with a rectal stump or 
intact rectum at screening/baseline and end of the study (Month 6).  One biopsy of rectal mucosa at 
each time will be placed in RNA later, and the remaining specimens will be flash frozen in liquid 
nitrogen.

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
38 
 
Research Specimen Summary 
Specimen 
Time Point(s) 
Processing 
Shipping 
Optional research 
blood: one 10 mL 
EDTA lavender -
topped and one 10 
mL red-topped tube 
Baseline/screening, 
Month 3, and 
Month 6 
Utilize BAP kits; Process into red-top tube into serum at site. 
Process lavender-topped tube into plasma and buffy coat at site. 
Freeze all specimens.   Place sample type on the label: P=plasma; B-
Buffy; S=Serum 
Ship to BAP FedExTM overnight, M-F, on 
dry ice. BAP will accession and store at -
80oC. 
Optional research 
blood: Two 10 mL 
EDTA lavender-
topped tube 
Baseline/screening, 
Month 3, and 
Month 6 
Utilize BAP kit.  Centrifuge, aliquot into intermediate tube, and 
centrifuge again to produce platelet poor plasma (PPP) per 
institutional lab procedures. Be sure to not disturb the residual 
blood cells carried over from the first centrifugation step when 
aliquoting PPP.  See BAP kit instructions for details. Freeze. 
Ship to BAP FedExTM overnight, M-F, on 
dry ice. BAP will accession and store at -
80oC. 
Optional urine 
specimen 
Baseline/screening, 
Month 3 and 
Month 6 
Utilize BAP kit; aliquot from collection container to tubes provided. 
Freeze. 
Ship to BAP FedExTM overnight, M-F, on 
dry ice. BAP will accession and store at -
80oC. 
Tissue if Spigelman 2: 
Baseline/screening 
and Month 6 
1. Four biopsies of normal duodenal mucosa and one biopsy of 
duodenal polyp. 
2. Place one normal duodenal mucosa biopsy and one polyp in 
RNAlater. Refrigerate at 4-6oC or snap freeze. 
3. Snap freeze remaining three specimens in separate cryovials in 
liquid nitrogen.  
4. Make sure labels distinguish normal duodenal mucosa versus 
polyp specimens. 
Ship frozen specimens to BAP FedExTM 
overnight, M-F, on dry ice.   
 
Ship specimen in RNALater to BAP on a 
cold pack (or dry ice if frozen).  Accession.  
Store specimens at -80oC until requested.  
Tissue if Spigelman 3: 
Baseline/screening 
and Month 6 
1. Four biopsies of normal duodenal mucosa and two biopsies of 
duodenal polyps. 
2. Place one normal duodenal mucosa biopsy and one polyp in 
RNAlater. Refrigerate at 4-6oC or snap freeze 
3. Snap freeze all remaining specimens in separate cryovials in 
liquid nitrogen (three normal duodenal mucosa and one polyp).  
4. Make sure labels distinguish normal duodenal mucosa versus 
polyp specimens. 
Ship frozen specimens to BAP FedExTM 
overnight, M-F, on dry ice.   
 
Ship specimens in RNALater to BAP 
FedExTM overnight, M-F, on a cold pack 
(or dry ice if frozen).  Accession.  Store 
specimens at -80oC until requested. 
Tissue if a rectal 
stump or intact 
rectum: 
Baseline/screening 
and Month 6 
1. Four biopsies of normal rectal mucosa 
2. Place one rectal mucosa biopsy in RNAlater and refrigerate at 
4-6oC or snap freeze 
3. Snap freeze the three remaining rectal biopsies in liquid 
nitrogen. 
Ship frozen specimens to BAP FedExTM 
BAP FedExTM overnight, M-F, on dry ice.   
Ship specimens in RNALater to BAP 
FedExTM overnight, M-F, on a cold pack 
(or dry ice if frozen).  Accession.  Store 
specimens at -80oC until requested. 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
39 
 
10.3 
Labeling and Shipping Instructions 
 
The pre-addressed shipping labels will be provided with the specimen kits.  Site teams are cautioned to 
make sure the correct specimen is sent to the correct location for analysis. 
 
 
 
 
 
 
All specimens must be labeled with the study number, participant ID, participant initials (if allowed per 
institutional policy), type of specimen (normal mucosa versus polyp), source of specimen (duodenum 
versus rectum), additive (RNALater versus none/snap frozen), date and time of collection. Abbreviations 
are allowed, if legible (see kit requisition form or instructions). 
 
Example:   
MAY2016-07-01 
Month 6 
CPN00023 
 
 
 
T O M 
 
 
 
mm/dd/2016, 14:30 
 
 
 
Duodenal polyp 
 
 
 
RNAlater 
 
All sections of the requisition form and specimen collection labels must be completed and legible.   
Specimen collection vial labels should match the requisition form exactly. 
 
All specimens should be sent over night (Monday through Friday) via FedEx® on dry ice or on a cold pack 
(See Research Specimen Summary Table, Section 10.2). Site staff will send an email with FedEx tracking 
number to the Biospecimen Resource Manager so arrangements can be made to receive the specimens 
and place immediately in appropriate storage facilities.  Exceptions for holidays will be communicated in 
advance to participating organizations.  All specimens must be shipped to the address provided on the 
specimen shippers and listed above (See Section 10.2). 
 
10.4 
Tissue Banking 
 
Biologic specimens collected during the conduct of each clinical trial that are not used during the course 
of the study will be considered deliverables under the contract and thus the property of the NCI.  
 
At study completion, remaining frozen biologic specimens will be labeled (study number, participant ID 
number, specimen type, specimen number, date of collection) batched, and shipped (overnight, M-F) for 
storage (until request is received to transfer to DCP Biospecimens Repository) to: 
 
Biospecimens Accessioning and Processing (BAP) Freezer 
ST SL-16, 150 Third Street Southwest, Rochester, MN  55902 
 
At study completion, NCI reserves the option to either retain or relinquish ownership of the unused 
biologic specimens. If NCI retains ownership of specimens, the Contractor shall collect, verify and 
transfer the requested biologic specimens from the site to a NCI-specified repository or laboratory at 
NCI’s expense.  
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
40 
 
11. 
REPORTING ADVERSE EVENTS  
 
DEFINITION: AE means any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign), 
symptom, or disease temporally associated with participation in a study, whether or not related to that 
participation. This includes all deaths that occur while a participant is on a study. 
 
Please note that all abnormal clinical laboratory values that are determined to be of clinical significance 
based on a physician’s assessment are to be reported as AEs. Those labs determined to be of no clinical 
significance or of unknown clinical significance (per the physician’s assessment) should not be reported 
as AEs. Any lab value of unknown clinical significance should continue to be investigated/followed-up 
further for a final determination, if possible. 
 
A list of AEs that have occurred or might occur  can be found in §6.2 Reported Adverse Events and 
Potential Risks, as well as the Investigator Brochure or package insert.  
 
11.1 
Adverse Events 
 
11.1.1 Reportable AEs 
 
All AEs that occur after the informed consent is signed and baseline assessments are completed 
(including run-in) must be recorded on the AE CRF (paper and/or electronic) whether or not related to 
study agent. 
 
11.1.2 AE Data Elements: 
 
The following data elements are required for AE reporting. 
• 
AE verbatim term 
• 
NCI Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) AE term 
(MedDRA lowest level term) 
• 
CTCAE (MedDRA) System Organ Class (SOC) 
• 
Event onset date and event ended date 
• 
Treatment assignment code (TAC) at time of AE onset 
• 
Severity grade 
• 
Attribution to study agent (relatedness) 
• 
Whether or not the event was reported as a SAE 
• 
Whether or not the subject dropped due to the event 
• 
Outcome of the event 
 
11.1.3  Severity of AEs 
 
 
 
11.1.3.1  Identify the AE using the CTCAE version 4.0. The CTCAE provides descriptive terminology 
(MedDRA lowest level term) and a grading scale for each AE listed. A copy of the CTCAE can be found at 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
41 
 
AEs will be assessed according to the grade associated with the CTCAE term. AEs that do not have a 
corresponding CTCAE term will be assessed according to the general guidelines for grading used in the 
CTCAE v4.0. as stated below.  
 
CTCAE v4.0 general severity guidelines:  
 
Grade 
Severity 
Description  
1 
Mild 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated. 
2 
Moderate 
Moderate; minimal, local or noninvasive intervention indicated; 
limiting age-appropriate instrumental activities of daily living (ADL)*. 
3 
Severe 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self-
care ADL**. 
4 
Life-threatening 
Life-threatening consequences; urgent intervention indicated. 
5 
Fatal 
Death related to AE. 
   
ADL 
 
*Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc. 
 
**Self-care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
 
11.1.4 Assessment of relationship of AE to treatment 
 
 
The possibility that the AE is related to study agent will be classified as one of the following: not related, 
unlikely, possible, probable, or definite. 
  
11.1.5 Follow-up of AEs 
 
All AEs, including lab abnormalities that in the opinion of the investigator are clinically significant, will be 
followed according to good medical practices and documented as such.  
 
11.2 
Serious Adverse Events  
 
11.2.1 DEFINITION: Regulations at 21 CFR §312.32 (revised April 1, 2014) defines an SAE as any 
untoward medical occurrence that at any dose has one or more of the following outcomes: 
 
• Death 
• A life-threatening AE 
• Inpatient hospitalization or prolongation of existing hospitalization 
• A persistent or significant incapacity or substantial disruption of the ability to perform normal 
life functions 
• A congenital anomaly or birth defect 
• Important medical events that may not be immediately life-threatening or result in 
death or hospitalization should also be considered serious when, based upon 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
42 
 
appropriate medical judgment, they may jeopardize the patient and may require 
intervention to prevent one of the other outcomes. 
 
11.2.2 Reporting SAEs to DCP 
 
11.2.2.1 The Lead Organization and all Participating Organizations will report SAEs following the current, 
active DCP SAE reporting SOP available at this location: http://prevention.cancer.gov/clinical-
trials/clinical-trials-management/protocol-information-office/pio-instructions-and-tools/2012-consortia. 
 
11.2.2.2  Contact the DCP Medical Monitor by phone within 24 hours of knowledge of the event.  
 
Gary Della’Zanna, D.O., M.Sc.  
National Institutes of Health, National Cancer Institute  
Division of Cancer Prevention  
9609 Medical Center Drive  
Bethesda, MD 20892  
Phone: 240-276-7042  
Fax (with cover sheet, Attn: Dr. G. Della’Zanna): 240-276-7848  
Email: dellazannagj@mail.nih.gov 
 
Include the following information when calling the Medical Monitor: 
• 
Date and time of the SAE 
• 
Date and time of the SAE report 
• 
Name of reporter 
• 
Call back phone number 
• 
Affiliation/Institution conducting the study 
• 
DCP protocol number 
• 
Title of protocol 
• 
Description of the SAE, including attribution to drug 
 
Guidance for the process of coding the SAE can be obtained by contacting the NCI MD Help Desk:  
adeersmd@tech-res.com 
 
11.2.2.3 The Lead Organization and all Participating Organizations will submit SAE reports, following 
the current, active DCP SAE reporting SOP within 48 hours of learning of the event: 
 
1. DCP Medical Monitor: dellazannagj@mail.nih.gov   
2. DCP’s Regulatory Contractor CCS Associates, Inc.: safety@ccsainc.com   
3. CPN Operations Office: cancerpreventionnetwork@mayo.edu   
   
Follow up information should also be sent to all of the above. 
 
11.2.2.4 The DCP Medical Monitor and CCSA regulatory and safety staff will determine which SAEs 
require FDA submission as IND safety reports. 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
43 
 
11.2.2.5 The Lead Organization and all Participating Organizations will comply with applicable regulatory 
requirements related to reporting SAEs to the IRB/IEC.  
 
11.2.3 Follow-up of SAE 
 
Site staff should send follow-up reports as requested when additional information is available. Follow-up 
information should be submitted to DCP as soon as available.  SAEs will be treated according to 
institutional standards of good clinical practice and followed to resolution.  
 
12. 
STUDY MONITORING 
 
12.1 
Data Management 
 
The Mayo Clinic Cancer Center database will be the database of record for the protocol and subject to 
NCI and FDA audit.  Minimum Data Sets will be submitted to DCP per contract requirements.  Please see 
2012 CPN Master Data Management Plan. 
 
12.2 
Case Report Forms 
 
Participant data will be collected using protocol-specific case report forms (CRF) utilizing NCI-approved 
Common Data Elements (CDEs). The approved CRFs will be used to create the electronic CRF (e-CRF) 
screens for data entry into the Mayo Clinic Cancer Center database. Amended CRFs will be submitted to 
the DCP Protocol Information Office for review and approval. 
 
12.3 
Source Documents 
 
A source document is any document, form, or record where specific participants’ data are first recorded.  
FDA [21 CFR 312.62 (b)] requires that the investigator “...prepare and maintain accurate case histories 
designed to record all observations and other data pertinent to the investigation on each individual 
treated with the investigational agent or employed as a control in the investigation.” Among many other 
items, source documents include:  
• 
Inpatient and outpatient medical records  
• 
Progress notes  
• 
Consults  
• 
Nursing notes  
• 
Pathology reports  
• 
Endoscopy reports  
• 
Medicine/radiation administration records  
• 
Surgical reports  
• 
Laboratory reports  
• 
Admission forms  
• 
Flow sheets and worksheets that are signed and dated  
• 
Protocol or study road maps  
• 
Appointment books  
• 
Participant diaries/calendars 
• 
Blood and tissue collection/submission and requisition forms (signed and dated). 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
44 
 
12.4 
Data and Safety Monitoring Plan 
 
The CPN Master DSMP is applicable to all studies within the CPN Consortium and provides detailed 
information regarding data and safety monitoring for this study.  The trial will be monitored closely for 
occurrence of adverse events by the study team and by the Mayo Clinic Cancer Center Data Safety 
Monitoring Board (DSMB). The DSMB (along with the study Medical Monitor) will be consulted 
regarding whether or not accrual should be suspended to allow for investigation in the occurrence of 
severe adverse events, particularly for those that are possibly, probably, or definitely related to the 
study agent. 
 
12.5 
Sponsor or FDA Monitoring 
 
The NCI, DCP (or their designee), pharmaceutical collaborator (or their designee), or FDA may 
monitor/audit various aspects of the study. These monitors will be given access to facilities, databases, 
supplies and records to review and verify data pertinent to the study.  
 
12.6 
Record Retention 
 
Clinical records for all participants, including CRFs, all source documentation (containing evidence to 
study eligibility, history and physical findings, laboratory data, results of consultations, etc.), as well as 
IRB records and other regulatory documentation will be retained by the Investigator in a secure storage 
facility in compliance with Health Insurance Portability and Accountability Act (HIPAA), Office of Human 
Research Protections (OHRP), Food and Drug Administration (FDA) regulations and guidances, and 
NCI/DCP requirements, unless the standard at the site is more stringent. The records for all studies 
performed under an IND will be maintained, at a minimum, for two years after the approval of a New 
Drug Application (NDA). For NCI/DCP, records will be retained for at least three years after the 
completion of the research. NCI will be notified prior to the planned destruction of any materials. The 
records should be accessible for inspection and copying by authorized persons of the Food and Drug 
Administration. If the study is done outside of the United States, applicable regulatory requirements for 
the specific country participating in the study also apply. 
 
12.7 
Cooperative Research and Development Agreement (CRADA)/Clinical Trials 
Agreement (CTA) 
 
Not applicable   
 
13. 
STATISTICAL CONSIDERATIONS 
 
13.1 
Study Design/Description 
 
This is a single arm Phase II trial designed to assess the effect of weekly erlotinib among FAP subjects.  
The primary objective of this trial is to assess the mean percent change in duodenal polyp burden (sum 
of diameters from all polyps) from baseline to 6 months post-intervention for FAP subjects receiving 
weekly erlotinib.  The hypothesis is that weekly erlotinib will significantly reduce duodenal polyp burden 
after 6 months of treatment.  If a significant reduction in polyp burden is shown after 6 months of 
treatment, we will also assess the grade 2/3 adverse event rate in this population and compare it to 
historical data.  The hypothesis is that weekly erlotinib will significantly reduce the grade 2/3 AE rate 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
45 
 
compared to historical control data.  Statistical considerations regarding sample size and study power 
are based on this primary study objective.  Secondary endpoints will evaluate all adverse events, assess 
the absolute and percent change in duodenal polyp number from baseline to 6 months, and assess the 
absolute and percent changes in lower gastrointestinal polyp burden and number within patient subsets 
of interest.   
 
There is limited Quality of Life (QOL) data on participants who participate in chemoprevention trials and 
we intend to create a databank of QOL information by administering the “Was It Worth It” (WIWI) 
questionnaire at trial completion across multiple trials. We will seek to evaluate participant perception 
of their experience in trial participation once we have a reasonable amount of information (large 
enough sample size). Since participants who participate in these chemoprevention trials are high risk but 
otherwise healthy, the WIWI tool would help answer simple questions about participants’ assessment of 
whether or not participation in this trial was “worth it.”  
 
13.2 
Randomization/Stratification  
 
There will be no randomization or stratification for this study.  This study will be a single arm Phase II 
trial, where all subjects will be accrued in one stage.   
 
13.3 
Accrual and Feasibility 
 
The study design requires a total of up to 70 participants for screening evaluation with approximately 60 
moving forward to registration and intervention due to anticipated screen failures of approximately 
15%.  We further expect up to 15% of participants to drop out or otherwise become non-evaluable by 6 
months such that approximately 50 subjects should be evaluable for the primary endpoint.  We expect 
to enroll an average of 1 participant per month for each of the participating CPN sites, for an overall 
registration rate of approximately 6 participants per month.  With this accrual rate and with a 6 month 
ramp up for participating organizations, we plan to complete accrual in about 18 months, which includes 
2 months for planned slowing of enrollment due to holidays, etc.  Accounting for patient follow-up, data 
entry, and analysis, the study should be completed within approximately 2.5 years.   
 
Planned Accrual Estimates 
 
 
 
Racial Categories 
DOMESTIC PLANNED ENROLLMENT REPORT 
Ethnic Categories 
Not Hispanic or Latino 
Hispanic or Latino 
 
Total 
Female 
Male 
Female 
Male 
American Indian/Alaska Native 
0 
0 
0 
0 
0 
Asian 
0 
1 
0 
0 
1 
Native Hawaiian or Other 
Pacific Islander 
0 
0 
0 
0 
0 
Black or African American 
4 
5 
1 
1 
11 
White  
14 
15 
7 
10 
46 
More Than One Race 
0 
1 
0 
1 
2 
Total 
18 
22 
8 
12 
60 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
46 
 
 
 
Racial Categories 
INTERNATIONAL (including Canadian participants) PLANNED 
ENROLLMENT REPORT 
Ethnic Categories 
Not Hispanic or Latino 
Hispanic or Latino 
 
Total 
Female 
Male 
Female 
Male 
American Indian/Alaska Native 
 
 
 
 
 
Asian 
 
 
 
 
 
Native Hawaiian or Other 
Pacific Islander 
 
 
 
 
 
Black or African American 
 
 
 
 
 
White  
 
 
 
 
 
More Than One Race 
 
 
 
 
 
Total 
 
 
 
 
0 
 
 
13.4 
Primary Objective, Endpoint(s), Analysis Plan 
  
The primary objective of this trial is to assess the mean percent change in duodenal polyp burden (sum 
of diameters from all polyps) from baseline to 6 months post-intervention for FAP subjects receiving 
weekly erlotinib.  The hypothesis is that weekly erlotinib will significantly reduce duodenal polyp burden 
after 6 months of treatment.  If a significant reduction in polyp burden is shown after 6 months of 
treatment, we will also assess the grade 2/3 adverse event rate in this population and compare it to 
historical data.  The hypothesis is that weekly erlotinib will significantly reduce the grade 2/3 AE rate 
compared to historical control data.  The study design below assesses the co-primary endpoints using a 
hierarchical testing strategy, where the AE primary endpoint will only be assessed if Polyp Burden is 
significantly reduced.  With this design strategy, we’re able to maintain alpha = 0.05 for each primary 
endpoint.   
 
Polyp Burden Primary Endpoint:    Based on the prior data from the FAPEST study, the sulindac/erlotinib 
arm had a 8.5-mm (38%) median decrease (38% decrease for mean as well) in polyp burden compared 
to a median increase of 8 mm (31%) in the placebo arm (44% mean increase). This difference was highly 
significant (p<0.001).20   
 
With 50 evaluable subjects, we would have 93% power to detect a significant mean percentage 
decrease in polyp burden from baseline of 15% for erlotinib weekly schedule, with 2-sided significance 
level of 0.05 (1 sample paired t-test).  This assumes an effect size of 50% and a standard deviation (SD) 
of 30%.  Basically, we could detect ½ a SD for this test, so if the SD ends up being 20%, we could detect a 
reduction of 10% or more in polyp burden.  For this test, we will assume the user-specified null 
hypothesis is 0%, so that we’re testing any significant reduction in polyp burden from baseline to 6 
months.  If for some reason, the sample size doesn’t meet target accrual of 50 evaluable subjects, here 
are some other possibilities for the same effect size and alpha.  With at least 34 eligible patients, we’d 
have at least 80% power for the polyp burden primary endpoint.  With at least 35 eligible patients, we’d 
have at least 80% power for both primary endpoints (polyp burden and AEs), just in case the accrual 
suffers and we need to stop the trial early.   
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
47 
 
Number Eligible 
Power 
34 
80% 
35 
81% 
40 
86% 
44 
90% 
 
AE Primary Endpoint (only tested if Polyp Burden is significantly reduced, otherwise not 
important):  The combination arm (sulindac and erlotinib daily) from the FAPEST study, showed much 
higher rates of grade 2/3 AEs (at least possibly related) compared to placebo (46% vs. 13%).  It also 
showed much higher rates of Rash for both grade 1-3 (87%) and grade 2-3 (26%) as compared to 
placebo (20% for grade 1-3 and 0% for grade 2-3).20  Since this study will be testing erlotinib weekly we 
hypothesize that the AE rates will be significantly lower than found in the aforementioned Samadder 
study.    
 
With 50 evaluable subjects, we would have 94% power to detect a reduction in grade 2/3 AE rate from 
50% to 25%, assuming a 2-sided significance level of 0.05.  This is based on an Exact test for a single 
proportion, assuming 50% as the user specified null hypothesis.  If for some reason, the sample size 
doesn’t meet target accrual of 50 evaluable subjects, here are some other possibilities for the same 
effect size and alpha.  All eligible participants who start treatment will be evaluable for the AE primary 
endpoint.   
 
With 44 eligible patients, we’d still have 93% power as well for this AE primary endpoint.   With 40 
eligible, we’d have 89% power, and with 35 eligible we’d have 83% power.  With at least 35 eligible 
patients, we’d have at least 80% power for both primary endpoints, just in case the accrual suffers and 
we need to stop the trial early.   
 
Number Eligible 
Power 
34 
78% 
35 
83% 
40 
89% 
44 
93% 
 
13.5 
Secondary Objectives, Endpoints, Analysis Plans 
 
• 
To evaluate all adverse events associated with the weekly erlotinib; 
• 
To assess the absolute and percent change in duodenal polyp number from baseline to 6 
months;   
• 
To assess the absolute and percent changes in lower gastrointestinal polyp burden and number 
for the subset of participants with ileal pouch anal anastomosis (IPAA) or ileo-rectal anastomosis 
with rectal stump (anticipated to be approximately 70% of registered cohort); and 
• 
To assess the absolute and percent change in desmoid tumor size in participants who have 
baseline and follow up CTs performed as part of their standard of care (anticipated to be 
approximately 30% of the registered cohort); 
• 
Gene expression profiles in duodenal adenomas and uninvolved tissue will be compared 
between baseline and endpoint samples using negative binomial statistics (DESeq2): 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
48 
 
o Identify differentially expressed genes between duodenal polyps and uninvolved tissue 
at endpoint compared to baseline; 
o Evaluate the effect of weekly erlotinib on EGFR and Wnt target gene expression in 
duodenal adenomas; 
o Evaluate the effect of weekly erlotinib on immune response signaling in duodenal 
adenomas and uninvolved tissue. 
 
The hypothesis is that weekly erlotinib treatment will reduce the number of differentially expressed 
genes and EGFR signaling in duodenal adenomas similar to findings from the previous erlotinib + 
sulindac study. We also anticipate Wnt signaling will be inhibited in duodenal polyps from patients on 
drug. Using Ingenuity pathway analysis (IPA, Qiagen) we will evaluate the effect of erlotinib on immune 
response signaling pathways (IFNG, IL12) previously observed to be enhanced in patients receiving 
erlotinib + sulindac. 
 
13.6 
Reporting and Exclusions 
 
All registered participants who start treatment and complete both the baseline and 6-month post-
baseline evaluation will be evaluable for the polyp burden primary endpoint of this study using the 
modified intent-to-treat principle.  We plan to over register by about 15% to ensure an adequate sample 
size in the primary analysis cohort.  There will be no imputation for missing data.  A summary and listing 
of all major protocol violations will be provided.  All details will be given in the final study report and/or 
manuscript.  Participants lost to follow-up will be censored on the last date of assessment (or contact) 
and as appropriate for analyses that are dependent upon length of study participation.  All eligible 
participants who start treatment will be evaluable for the AE primary endpoint.   
 
13.7 
Evaluation of Toxicity (Secondary endpoint) 
 
All registered and treated participants will be evaluable for adverse events (AEs) from the time of their 
first dose of weekly erlotinib treatment.  To evaluate the AE profile for this treatment, the maximum 
grade for each type of adverse event will be recorded for each participant and frequency tables will be 
reviewed to determine the overall patterns. The number and severity of adverse events will be 
tabulated and summarized across all grades.  Grade 2+ adverse events will be similarly described and 
summarized separately.  As per NCI CTC Version 4.0, toxicities are defined as adverse events that are 
classified as either possibly, probably, or definitely related to the interventional agent.  Overall toxicity 
incidence, as well as toxicity profiles will be explored and summarized. Frequency distributions, 
graphical techniques, and other descriptive measures will form the basis of these analyses. In addition, 
we will review all adverse event data that are graded as 3, 4, or 5 and classified as either “unrelated or 
unlikely to be related” to the study intervention in the event of an actual relationship developing. 
 
13.7.1 Adverse Event Stopping Rule 
 
The trial will be monitored closely for occurrence of adverse events by the study team and by the Mayo 
Clinic Cancer Center Data Safety and Monitoring Board (DSMB) using the adverse event (AE) stopping 
rule specified below.   
 
Adverse Event Stopping Rule: The stopping rule specified below is based on the knowledge available at 
study development. We note that the Adverse Event Stopping Rule may be adjusted in the event of 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
49 
 
either (1) the study re-opening to accrual after any temporary suspension or (2) at any time during the 
conduct of the trial and in consideration of newly acquired information regarding the adverse event 
profile of the treatment(s) under investigation. The study team in consultation with the Mayo DSMB 
may also choose to suspend accrual because of unexpected adverse event profiles that have not crossed 
the specified rule below. 
 
Accrual will be temporarily suspended to this study if at any time we observe events considered at least 
possibly related to study treatment (i.e., an adverse event with attribute specified as "possible", 
"probable", or "definite") that satisfy any of the following criteria: 
 
• 
If, at any time, two of the initial 20 treated participants or 10% of all participants, i.e. when 
accrual is greater than 20 participants, have experienced a Grade 4 adverse event 
• 
If, at any time, a Grade 5 event occurs that is at least possibly related to treatment 
• 
In addition, each Grade 5 event, regardless of attribution, will be reviewed on a case-by-case 
basis in a real-time fashion to determine whether or not study accrual should be suspended. We 
also will review all Grade 4 adverse events, regardless of attribution, to monitor the emergence 
of any previously unrecognized treatment-related adverse events.  
 
13.8 
Evaluation of Response 
 
All registered participants who start treatment and complete both the baseline and 6-month post-
baseline evaluation will be evaluable for the polyp burden primary endpoint of this study using the 
modified intent-to-treat principle.  All conclusions regarding efficacy will be based on all participants 
who completed both the baseline and 6-month post-baseline evaluations.  Sub-analyses may be 
performed on the subsets of participants, excluding those for whom major protocol deviations have 
been identified (e.g., early death due to other reasons, early discontinuation of intervention, major 
protocol violations, etc.).  However, sub-analyses may not serve as the basis for drawing conclusions 
concerning efficacy, and the reasons for excluding participants from the analysis should be clearly 
reported.  For all measurements of response (i.e. the polyp burden primary endpoint), the 95% 
confidence intervals will also be provided.  All eligible patients who start treatment will be evaluable for 
the AE primary endpoint.   
 
13.9 
Interim Analysis 
 
Not applicable for this study.   
 
13.10 Ancillary Studies 
 
Laboratory measures will be correlated with participant outcomes (i.e., polyp burden, adverse events) 
and with each other as well.  Cut-points will be determined based on previously defined and accepted 
standards.  Descriptive statistics and simple scatter plots will be generated to review the tissue-based 
biomarker data.  For continuous variables, the actual and % change in the level of each of the 
biomarkers from pre- to post-intervention will be explored using Wilcoxon signed rank tests, and paired 
sample t-tests.  All categorical variables will be analyzed using chi-square tests or Fisher’s exact test.  For 
all translational endpoints, any notable statistical result will be viewed as an impetus for further study 
rather than as a definitive finding in and of itself. 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
50 
 
14. 
ETHICAL AND REGULATORY CONSIDERATIONS 
 
14.1 
Form FDA 1572 
 
Prior to initiating this study, the Protocol Lead Investigator at the Lead or Participating Organization(s) 
will provide a signed Form FDA 1572 stating that the study will be conducted in compliance with 
regulations for clinical investigations and listing the investigators, at each site that will participate in the 
protocol. All personnel directly involved in the performance of procedures required by the protocol and 
the collection of data should be listed on Form FDA 1572. 
 
14.2 
Other Required Documents 
 
14.2.1 Current (within two years) CV or biosketch for all study personnel listed on the Form FDA 1572 
and Delegation of Tasks form for the Lead Organization and all Participating Organizations.  
 
14.2.2 Current medical licenses (where applicable) for all study personnel listed on Form FDA 1572 and 
Delegation of Tasks form for the Lead Organization and all Participating Organizations. 
 
14.2.3 Lab certification (e.g., CLIA, CAP) and lab normal ranges for all labs listed on Form FDA 1572 for 
the Lead Organization and all Participating Organizations. 
 
14.2.4 Documentation of training in Good Clinical Practice for all study personnel listed on the FDA 
Form 1572 and Delegation of Tasks form for the Lead Organization and all Participating Organizations. 
 
14.2.5 Documentation of Federalwide Assurance (FWA) number for the Lead Organization and all 
Participating Organizations. 
 
14.2.6 Signed Investigator’s Brochure/Package Insert acknowledgement form 
 
14.2.7 Delegation of Tasks form for the Lead Organization and all Participating Organizations signed by 
the Principal Investigator for each site and initialed by all study personnel listed on the form 
 
14.2.8 Signed and dated NCI, DCP Financial Disclosure Form for all study personnel listed on Form FDA 
1572 for the Lead Organization and all Participating Organizations 
 
14.3 
Central Institutional Review Board Approval 
 
Prior to initiating the study and receiving agent, the Investigators at the Lead Organization and the 
Participating Organization(s) must obtain written approval to conduct the study from the appropriate 
CIRB. Should changes to the study become necessary, protocol amendments will be submitted to the 
DCP PIO according to DCP Amendment Guidelines. The DCP-approved amended protocol must be 
approved by the IRB prior to implementation 
 
14.4 
Informed Consent 
 
All potential study participants will be given a copy of the IRB-approved Informed Consent to review. 
The investigator will explain all aspects of the study in lay language and answer all questions regarding 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
51 
 
the study. If the participant decides to participate in the study, he/she will be asked to sign and date the 
Informed Consent document. The study agent(s) will not be released to a participant who has not signed 
the Informed Consent document. Subjects who refuse to participate or who withdraw from the study 
will be treated without prejudice. 
 
Participants must be provided the option to allow the use of blood specimens, other body fluids, and 
tissues obtained during testing, operative procedures, or other standard medical practices for further 
research purposes. If applicable, statement of this option may be included within the informed consent 
document or may be provided as an addendum to the consent. A Model Consent Form for Use of Tissue 
for Research is available through a link in the DCP website. 
 
Prior to study initiation, the informed consent document must be reviewed and approved by NCI, DCP, 
the Consortium Lead Organization, and the IRB at each Organization at which the protocol will be 
implemented. Any subsequent changes to the informed consent must be approved by NCI, DCP, the 
Consortium Lead Organization’s IRB, and then submitted to each organization’s IRB for approval prior to 
initiation. 
 
14.5 
Submission of Regulatory Documents 
 
All regulatory documents are collected by the Consortia Lead Organization and reviewed for 
completeness and accuracy. Once the Consortia Lead Organization has received complete and accurate 
documents from a participating organization, the Consortium Lead Organization will forward the 
regulatory documents to DCP’s Regulatory Contractor: 
 
 
Paper Document/CD-ROM Submissions: 
 
Regulatory Affairs Department 
 
CCS Associates, Inc. 
 
2001 Gateway Place, Suite 350 West 
 
San Jose, CA 95110 
 
Phone: 650-691-4400 
 
Fax: 650-691-4410 
 
 
E-mail Submissions: 
 
regulatory@ccsainc.com 
 
Regulatory documents that do not require an original signature may be sent electronically to the 
Consortium Lead Organization for review, which will then be electronically forwarded to DCP’s 
Regulatory Contractor. 
 
14.6 
Other 
 
This trial will be conducted in compliance with the protocol, Good Clinical Practice (GCP), and the 
applicable regulatory requirements. 
 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
52 
 
15. 
FINANCING, EXPENSES, AND/OR INSURANCE 
 
No expenses will be incurred by the study participants and/or their insurance carriers.  This does not 
include costs of tests and procedures that are a part of the participant’s normal clinical care.  This also 
does not include any injuries or illnesses the participant may have related to their participation on the 
study.  In the event of an injury or illness, the study participant and/or their insurance carrier will be 
responsible for all expenses related to the injury or illness.  Participants may be provided remuneration 
for their participation in the study, at the discretion of the local Institutional Review Board. 
 
REFERENCES 
 
1. 
Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, 
Offerhaus GJ. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous 
polyposis. The New England journal of medicine 1993;328:1313-6. 
2. 
Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, 
Geiman DE, Hubbard W, Offerhaus GJ, Hamilton SR. Primary chemoprevention of familial 
adenomatous polyposis with sulindac. The New England journal of medicine 2002;346:1054-9. 
3. 
Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RK. Effect of sulindac on small polyps in 
familial adenomatous polyposis. Lancet 1995;345:855-6. 
4. 
Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of 
the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with 
familial adenomatous polyposis. The British journal of surgery 1993;80:1618-9. 
5. 
Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, 
Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B, Steinbach G. A 
randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 
inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857-60. 
6. 
Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, 
Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B. 
Celecoxib for the prevention of colorectal adenomatous polyps. The New England journal of 
medicine 2006;355:885-95. 
7. 
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders 
B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King 
KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW, Kelloff 
G. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. The 
New England journal of medicine 2000;342:1946-52. 
8. 
M N. Pfizer, Inc.; Withdrawal of Approval of Familial Adenomatous Polyposis Indication for 
CELEBREX. In: Register OotF, ed. Volume 2015. New York, NY: P, 2012. 
9. 
Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, 
DuBois RN, Jetton TL, Morrow JD. Epidermal growth factor receptor activation induces nuclear 
targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in 
polarizing colon cancer cells. Proceedings of the National Academy of Sciences of the United 
States of America 1997;94:657-62. 
10. 
Eisinger AL, Nadauld LD, Shelton DN, Peterson PW, Phelps RA, Chidester S, Stafforini DM, 
Prescott SM, Jones DA. The adenomatous polyposis coli tumor suppressor gene regulates 
expression of cyclooxygenase-2 by a mechanism that involves retinoic acid. The Journal of 
biological chemistry 2006;281:20474-82. 
11. 
Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, Threadgill DW. Importance of 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
53 
 
epidermal growth factor receptor signaling in establishment of adenomas and maintenance of 
carcinomas during intestinal tumorigenesis. Proceedings of the National Academy of Sciences of 
the United States of America 2002;99:1521-6. 
12. 
Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. 
Gastroenterology 2010;138:2044-58. 
13. 
Biasco G, Pantaleo MA, Di Febo G, Calabrese C, Brandi G, Bulow S. Risk of duodenal cancer in 
patients with familial adenomatous polyposis. Gut 2004;53:1547; author reply 1547. 
14. 
Bulow S, Bjork J, Christensen IJ, Fausa O, Jarvinen H, Moesgaard F, Vasen HF. Duodenal 
adenomatosis in familial adenomatous polyposis. Gut 2004;53:381-6. 
15. 
Offerhaus GJ, Giardiello FM, Krush AJ, Booker SV, Tersmette AC, Kelley NC, Hamilton SR. The risk 
of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 
1992;102:1980-2. 
16. 
Jagelman DG, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer in familial adenomatous 
polyposis. Lancet 1988;1:1149-51. 
17. 
Vasen HF, Bulow S, Myrhoj T, Mathus-Vliegen L, Griffioen G, Buskens E, Taal BG, Nagengast F, 
Slors JF, de Ruiter P. Decision analysis in the management of duodenal adenomatosis in familial 
adenomatous polyposis. Gut 1997;40:716-9. 
18. 
Heiskanen I, Kellokumpu I, Jarvinen H. Management of duodenal adenomas in 98 patients with 
familial adenomatous polyposis. Endoscopy 1999;31:412-6. 
19. 
Conio M, Gostout CJ. Management of duodenal adenomas in 98 patients with familial 
adenomatous polyposis. Gastrointestinal endoscopy 2001;53:265-6. 
20. 
Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, Jones D, Tavtigian SV, 
Done MW, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Davis R, Topham MK, Lynch P, 
Strait E, McKinnon W, Burt RW, Kuwada SK. Effect of Sulindac and Erlotinib vs Placebo on 
Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial. JAMA 
2016;315:1266-75. 
21. 
Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, Sica G, Muller S, Moreno-Williams R, 
Lewis M, Grist W, Chen AY, Moore CE, Owonikoko TK, Ramalingam S, Beitler JJ, Nannapaneni S, 
Shin HJ, Grandis JR, Khuri FR, Chen ZG, Shin DM. Chemoprevention of head and neck cancer with 
celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer prevention 
research 2014;7:283-91. 
22. 
Lubet RA, Szabo E, Iwata KK, Gill SC, Tucker C, Bode A, Steele VE, Juliana MM, Nicastro HL, 
Grubbs CJ. Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced 
mammary carcinogenesis. Cancer prevention research 2013;6:448-54. 
23. 
Milton DT, Azzoli CG, Heelan RT, Venkatraman E, Gomez JE, Kris MG, Krug LM, Pao W, Rizvi NA, 
Dunne M, Miller VA. A phase I/II study of weekly high-dose erlotinib in previously treated 
patients with nonsmall cell lung cancer. Cancer 2006;107:1034-41. 
24. 
Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB. 
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung 
cancer. Neuro-oncology 2011;13:1364-9. 
25. 
Hyman N, Waye JD. Endoscopic four quadrant tattoo for the identification of colonic lesions at 
surgery. Gastrointestinal endoscopy 1991;37:56-8. 
26. 
Shatz BA, Thavorides V. Colonic tattoo for follow-up of endoscopic sessile polypectomy. 
Gastrointestinal endoscopy 1991;37:59-60. 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
54 
 
 
Summary of Changes – Informed Consent Form 
 
NCI Protocol #:  MAY2016-07-01 
Local Protocol #: MAY2016-07-01 
Protocol Version Date:  July 22, 2019 
 
Protocol Title:   Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden 
Associated with Familial Adenomatous Polyposis 
 
Informed Consent Version Date:  July 22, 2019 
 
Please note that the page numbers in the table below refer to the Word version of the 
Informed Consent Form that will be submitted to the CIRB. 
 
 
There are no changes in the informed consent template other than the version number and date. 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
55 
 
 
NCI, DCP CONSENT FORM TEMPLATE FOR CONSORTIA CANCER 
CHEMOPREVENTION TRIALS 
 
Study Title for Study Participants:  Testing Weekly Erlotinib for Familial 
Adenomatous Polyposis (FAP) 
 
Official Study Title for Internet Search on http://www.ClinicalTrials.gov: Phase II 
Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated 
with Familial Adenomatous Polyposis 
 
Introduction  
 
This is a clinical trial, a type of research study. Your study doctor will explain the clinical trial to 
you. Clinical trials include only people who choose to take part in the research. Please take your 
time to make your decision about volunteering. You may discuss your decision with your friends 
and family. You can also discuss this study with your health care team. If you have any 
questions, you can ask your study doctor for more of an explanation. You should only agree to 
participate in this study when you are comfortable enough with the information so that you can 
make an informed decision about joining. 
 
What is the usual approach to my Familial Adenomatous Polyposis (FAP)?  
 
You are being asked to take part in this study because you have FAP and are at increased risk 
for developing colon cancer. People who are at increased risk and choose not to participate in a 
study are usually followed closely by their doctor, with regular examinations of their colon, 
rectum, and small bowel to watch for the development of polyps and cancer. 
 
What are my other choices if I do not take part in this study?  
 
If you decide not to take part in this study, you have other choices. For example: 
• you may choose to have the usual approach described above, 
• you may choose to take part in a different study, if one is available,  
• or you may choose to do nothing. 
 
Why is this study being done? 
 
The purpose of this study is to test the safety of erlotinib (Tarceva®) taken once per week and 
find out what effects, if any, erlotinib has on people and their risk of colon cancer. There will be 
about 60 people taking part in this study.  

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
56 
 
 
Erlotinib (Tarceva®) is a targeted cancer therapy drug that interferes with the growth and 
spread of cancer cells in the body.  Targeted cancer therapies “target” cancer cells while doing 
little damage to normal cells.  Erlotinib has been effective in treating many different kinds of 
cancer, including lung and pancreatic cancer, and is approved by the FDA for targeted cancer 
therapy.  It is not approved for cancer prevention.  
 
Several recent studies have shown that erlotinib may also be effective in reducing the number 
of polyps and increasing the time to reappearance of polyps.  This study will test a weekly dose 
of erlotinib, instead of a daily dose, to see if it works just as well with fewer worrisome side 
effects.  Because Erlotinib has not been approved for reduction of polyps, using it for this study 
is experimental. 
 
Everyone participating in the study will be given the same dose of erlotinib, which will be 350 
mg (two 150 mg tablets plus two 25 mg tablets) once every week for 6 months.   
 
How long will I be in this study? 
 
You will be on the study for up to 8 months. After signing this informed consent document, you 
will have several tests to find out if you can take the study drug.  This may take up to 28 days 
before you begin taking the study drug. You will receive the study drug for 6 months.  Even if 
you do not finish the study, your doctor will continue to watch you for side effects and follow 
your condition for one additional month.  
 
What extra tests and procedures will I have if I take part in this study? 
 
Before you begin the study: 
You will sign this document, and you will be “pre-registered” and assigned your unique 
participant identification (PID) number.  From that point forward, all of your information and 
specimens will be identified only with this number. Some of the exams, tests, and procedures 
you will have are part of the usual approach for your condition. However, there are some extra 
examinations, blood tests, and procedures that you will need to have if you take part in this 
study. 
 
You will need to have the following extra evaluations and procedures to find out if you can be in 
the study:  
• 
We will review your medical and surgical history. 
• 
We will review of any medications you are taking and any symptoms you are experiencing. 
• 
Blood and urine will be collected for tests to check your health and how well your organs 
function. 
• 
Assessment of your alcohol and tobacco use 
• 
Optional: Blood and urine will be collected for research. 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
57 
 
• 
A pregnancy test will be performed within 7 days prior to registration if you are capable of 
having children. 
• 
Esophagogastroduodenoscopy (EGD) and lower gastrointestinal endoscopy procedures will 
be performed to look at your digestive system and evaluate any polyps that are present 
• 
Biopsies of your digestive tract will be collected for research 
• 
If you have been diagnosed with desmoid tumors and have CT (computed tomography) 
imaging at least twice yearly as part of your standard clinical care, copies of the CT images 
and the written reports will be collected. 
 
During the biopsy procedures, small pieces of tissue are removed in a similar way to biopsies 
done for diagnosis.  These will be tested and compared to pieces of tissue collected at the end 
of the study. We are looking for any changes that might have been caused by the study drug. 
 
If all of the exams, tests, and procedures show that you can take part in the study, and you 
choose to, then you will be provided with: 
• Study drug 
• A diary to record the study drug you’ve taken and any symptoms or side effects that you 
might experience 
• Instructions for taking the study drug and completing the diary   
• Prescriptions for medications, such as skin cream and antibiotics, to take if needed to help 
relieve any of the expected symptoms, if they occur. 
 
During the study: 
During the study, you will take erlotinib once week, on the same day and approximately the 
same time each week.  You should take the erlotinib at least one hour before or two hours after 
eating any food.  You will be required to keep a diary that notes taking this medication and any 
other medications you take. 
 
As part of this study you will also be asked to answer questions about your tobacco and alcohol 
use, both before you begin the study and again at the Month 6 visit.  Researchers want to see if 
tobacco and alcohol use affects the side effects people might get while on this study, or if 
tobacco and alcohol use modifies the effects of the study agents. 
 
Month 1:  You will return for a visit, physical exam, review of your medication diary, review of 
any symptoms you are experiencing and any medications you are taking.  Blood and urine will 
be collected to check for safety and toxicity. 
 
Approximately Months 2, 4, and 5:  You will receive a phone call from the study team to see 
how you are doing.  You will be asked about any symptoms you are experiencing and any 
medications you are taking. 
 
Month 3:  You will return for a visit, physical exam, review of your medication diary, review of 
any symptoms you are experiencing and any medications you are taking.  Your left over study 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
58 
 
drug will be collected, and you will be provided with a new supply.  Blood and urine will be 
collected to check for safety and toxicity. Additional optional blood and urine will be collected 
for research.  A pregnancy test will be performed if you are a woman capable of having 
children. 
 
Month 6 (of if you discontinue participation in the study early for any reason):  You will return 
for a visit, physical exam, review of your medication diary, review of any symptoms you are 
experiencing and any medications you are taking.  You will be asked to complete follow-up 
assessments of your alcohol and tobacco use, which will take about 10 minutes.  Your 
medication diaries and left over study drug will be collected.  Optional blood and urine will be 
collected for research. Blood and urine will be collected to check for safety and toxicity.  A 
pregnancy test will be performed if you are a woman capable of having children. You will also 
have another EGD, endoscopy, and biopsy collection to look at your digestive system and 
evaluate any polyps that are present.  You will be asked to complete a short questionnaire 
about your experience on this study (Was It Worth It?), which should take less than 5 minutes. 
 
If you have been diagnosed with desmoid tumors and have CT (computed tomography) imaging 
at least twice yearly as part of your standard clinical care, copies of the CT images and the 
written reports will be collected. 
 
Approximately Month 7:  You will be asked about any symptoms you are experiencing and any 
medications you are taking.  If any of the lab tests done at Month 6 were abnormal, they will be 
repeated at this visit.  This visit may be done by telephone if there were no abnormal lab test 
results. 
 
A study calendar is attached to this document that shows when these tests and procedures will 
take place. 
 
What possible risks can I expect from taking part in this study?  
If you choose to take part in the study, there is a risk that you may: 
• Lose time at work or home and spend more time in the hospital or doctor’s office than 
usual 
• Be asked sensitive or private questions which you normally do not discuss, for example 
about your tobacco and alcohol use 
• There can also be a risk in finding out new genetic information about you. New health 
information about inherited traits that might affect you or blood relatives could be 
found during a study. 
 
The erlotinib used in this study may affect how different parts of your body work, such as your 
liver, kidneys, heart, and blood. The study doctor will be testing your blood and urine and will 
let you know if changes occur that may affect your health.  There is also a risk that you could 
have side effects.  

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
59 
 
Here are important points about side effects: 
• The study doctors do not know who will or will not have side effects. 
• Some side effects may go away soon, some may last a long time, or some may never go 
away.  
• Some side effects may interfere with your ability to have children. 
• Some side effects may be serious and may even result in death.  
 
Here are important points about how you and the study doctor can make side effects less of a 
problem: 
• Tell the study doctor if you notice or feel anything different so they can see if you are 
having a side effect. 
• The study doctor may be able to treat some side effects. 
• The study doctor may adjust the study drugs to try to reduce side effects. 
 
The tables below show the most common side effects that we know about erlotinib, some of 
which may be serious. There might be other side effects that we do not yet know about. If 
important new side effects are found, the study doctor will discuss these with you. 
 
Possible Side Effects of erlotinib 
COMMON, SOME MAY BE SERIOUS 
In 100 people receiving erlotinib, more than 20 may have: 
• Red and bumpy skin that may itch (Rash) 
• Loose stool (Diarrhea) 
• Decreased appetite or not feeling hungry (Anorexia) 
• Difficulty breathing or shortness of breath (Dsypnea) 
• Cough 
• Feeling sick to your stomach (Nausea)  
• Infection 
• Throwing up (Vomiting) 
• Tiredness or fatigue 
 
 
 
 
 
 
 
 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
60 
 
OCCASIONAL, SOME MAY BE SERIOUS 
In 100 people receiving erlotinib, from 4 to 20 may have: 
• Sores in the mouth (oral mucositis) 
• Itching 
• Acne 
• Dry skin 
• Weight loss 
• Irritation (redness, swelling, warmth, and pain) or infection of the skin around 
fingernails or toenails 
• Eye infection/pink eye 
• Dry eyes 
• Stomach pain or pain in the abdomen (belly) 
• Red bumps on the skin that are red, sore, and possibly infected 
 
 
 
 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
61 
 
 
 
RARE, SOME MAY BE SERIOUS 
In 100 people receiving erlotinib, 3 or fewer may have: 
Although very rare, some of the side effects listed below can cause death. 
• Abnormal laboratory result which may indicate liver damage 
• Liver damage 
• Kidney damage which may cause swelling, may require dialysis 
• Swelling, irritation, or scarring of the lungs, which may cause pain or difficulty 
breathing 
• A tear or hole in the stomach that may require surgery. More common in people 
with ulcers (sores in the stomach), diverticulitis (redness, pain, and swelling of part of 
the belly), and in people who take some types of drugs (NSAIDS, corticosteroids, 
chemotherapy). Talk to your study doctor about drugs to avoid. 
• Severe blistering or peeling of the skin 
• Patches of skin may become darker in color 
• Redness, swelling, sores, or a tear or hole in the eye which may cause pain or blurred 
vision 
• Increased bleeding (internal bleeding, nose bleed). More common in people who 
take blood thinning drugs. 
• Increased body hair growth, hair loss, eyelash/eyebrow changes, or brittle/loose 
fingernails or toenails 
• Severe diarrhea or vomiting can cause an imbalance of minerals in the blood (called 
electrolytes) such as low potassium, with symptoms that may include weakness, 
fatigue, muscle cramps, or constipation 
• 
In people with cancer of the pancreas who took combined treatment of erlotinib plus 
gemcitabine: heart attack, stroke, fever, decreased red blood cells (anemia), which 
may cause tiredness or may require blood transfusion, and decreased platelets which 
may cause easy bleeding, or longer bleeding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
62 
 
 
 
 
POSSIBLE, SOME MAY BE SERIOUS 
The frequency of some individual side effects has not yet been determined: 
• Shoulder pain 
• Change in urine color 
• Indigestion 
• Gas in the belly, burping 
• Irritability (easily annoyed or made angry) 
• Swelling of the face, hands, feet, or ankles 
• Runny nose 
• Dizziness 
• Headache 
• Blood clot in the lung which may cause pain, shortness of breath 
• Stroke (stoppage of blood flow to your brain which may cause paralysis, weakness, 
headache) 
• Death or injury to unborn baby 
• 
Because of the potential harm to the infant, women should be advised against breast-
feeding while receiving erlotinib therapy 
 
Risks of the blood draw: You may have pain, bruising, a blood clot, or rarely, an infection at the 
site of the needle stick.  You may be asked to avoid donating blood during and for one month 
after you stop taking a study drug. 
 
Risks of the EGD/Lower endoscopy with biopsies:  There is a very small risk that the scope may 
cause a hole in the wall of your throat or stomach.  If that were to happen, the doctor will 
arrange for surgery to repair it.  There is a very small risk of bleeding related to the biopsy. 
 
There is a small risk that you will have a reaction to the drugs that are given to make you more 
comfortable during the EGD procedure.  You may have slowed breathing, a slowed heart rate, 
or you may feel sick to your stomach as the drugs wear off. 
 
You should not drive, sign legal documents, or perform other similar activities for 24 hours after 
the procedure. You will need to arrange for someone to drive you home after the EGD 
procedures. 
 
Reproductive risks: You should not get pregnant, breastfeed, or father a baby while in this 
study and for at least 14 days after stopping the study drug. The study drug, erlotinib, used in 
this study could be very damaging to an unborn baby. Check with the study doctor about what 
types of birth control, or pregnancy prevention, to use while in this study. 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
63 
 
Foods, medications, and activities that should be avoided during the study: There are a few 
foods, medications, and activities that may have an impact on the effectiveness of the study 
drug. 
• While participating in the study, you should avoid grapefruit-containing products such 
as grapefruits, grapefruit juice, and any sodas that contain grapefruit juice (Fresca® and 
Squirt®). 
• While participating in the study, you must not smoke or use any tobacco products.  
Urine tests will be done to check your exposure to tobacco and tobacco smoke.  
Smoking interferes with the way erlotinib works. 
• While participating in the study, you must not take more than 81 mg aspirin (1 baby 
aspirin) per day or more than 650 (two adults-sized tablets) per week. 
• While participating in the study, you must not take medications that change the acidity 
of your digestive tract, such as Protocol Pump Inhibitors (PPIs) for gastric reflux.  If you 
have a prescription for a PPI, and your doctor believes it is safe, an alternative 
medication can be suggested.   However, you will still have to skip this medication on 
the day before and the day of your erlotinib dose. 
• While participating in the study, you must be sure to inform the study team of any new 
medications, including over-the-counter medications, prescription drugs, and dietary 
supplements. 
 
What possible benefits can I expect from taking part in this study?  
 
This study may or may not help you because we do not know how the study drugs will compare 
to the usual approach for your condition. This study may help us learn things that could help 
people in the future. 
 
Can I stop taking part in this study? 
 
Yes. You can decide to stop at any time. If you decide to stop for any reason, it is important to 
let the study doctor know as soon as possible so you can stop safely. If you stop, you can decide 
whether or not to let the study doctor continue to provide your medical information to the 
organization running the study. 
 
For the tobacco and alcohol use questions, you can decide to not answer some or all of the 
questions. Your decision will not affect whether you can participate in the study, and it will not 
affect your relationship with your doctor or the study staff. 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
64 
 
The study doctor will tell you about any new information or changes in the study that could 
affect your health or your willingness to continue in the study. 
 
The study doctor may take you out of the study: 
• If your health changes.  
• If the study is no longer in your best interest. 
• If new information becomes available. 
• If you do not follow the study rules. 
• If the study is stopped early for any reason by the sponsor, IRB or FDA. 
 
What are my rights in this study?  
Taking part in this study is your choice. No matter what decision you make, and even if your 
decision changes, there will be no penalty to you. You will not lose medical care or any legal 
rights. 
 
For questions about your rights while in this study, call the Institutional Review Board at 
<telephone number>.  
 
What are the costs of taking part in this study?  
 
The erlotinib will be supplied at no charge while you take part in this study. The cost of study-
specific biopsies and exams, tests, and any other procedures will be paid for by the study. 
 
Some costs associated with your care may be considered standard of care, and will be billed to 
you or your insurance company. You will have to pay for any costs (including deductibles and 
co-payments) not covered by your health insurer. 
 
The study will pay for the following: 
• Erlotinib 
• Medications to help manage common side effects 
• Physical exams 
• Blood and urine tests 
• Blood and urine collection for optional research 
• Pregnancy tests, if applicable 
• EGD and/or lower GI Endoscopy exams that do not occur at time points that are the 
same as your usual and routine clinical care 
• Questionnaires and medication diaries 
• Phone calls to check on side effects and symptoms 
 
You or your insurance company will pay for the following: 
• Medications needed to manage uncommon or severe side effects, if they occur 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
65 
 
• EGD and/or lower GI Endoscopy exams, if they are completed at a time point that is the 
same as your usual and routine clinical care 
 
Before you decide to be in the study, you should check with your health plan or insurance 
company to find out exactly what they will pay for.  
 
Will I be paid for participating in this study? 
 
You will not be paid for participating in this study.  However, at the end of your study 
participation, you may receive a payment of up to $400 to help cover expenses related to study 
participation.  If you complete only part of the study, you will receive part of this total payment.  
For example, if you complete half (3 months) of the study, you would receive half of the total 
payment. 
  
What happens if I am injured or hurt because I took part in this study? 
 
If you feel you have been injured or hurt as a result of taking part in the study, it is important 
that you tell the study doctor immediately. You will get medical treatment if you are injured or 
hurt as a result of taking part in this study.  
 
The study sponsors will not offer to pay for medical treatment for injury. Your insurance 
company may not be willing to pay for study-related injury. If you have no insurance coverage, 
you would be responsible for any costs. Even though you are in a study, you keep all of your 
legal rights to receive payment for injury caused by medical errors. 
 
Who will see my medical information?  
 
Your privacy is very important to us.  The study doctors will make every effort to protect it.  The 
study doctors have a privacy permit to help protect your records if there is a court case.  
However, some of your medical information may be given out if required by law.  If this should 
happen, the study doctors will do their best to make sure that any information that goes out to 
others will not identify who you are.  
 
Some of your health information, such as your response to cancer treatment, results of study 
tests, and medicines you took, will be kept by the study sponsor in a central research database.  
However, your name and contact information will not be put in the database.  If information 
from this study is published or presented at scientific meetings, your name and other personal 
information will not be used.  
 
There are organizations that may look at your study records.  Your health information in the 
research database also may be shared with these organizations.  They must keep your 
information private, unless required by law to give it to another group.   
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
66 
 
There are organizations that may inspect your records. These organizations are required to 
make sure your information is kept private. Some of these organizations are: 
• 
The study sponsor, National Cancer Institute, Division of Cancer Prevention  
• 
The Central Institutional Review Board, CIRB, is a group of people who review the 
research with the goal of protecting the people who take part in the study. 
• 
The Food and Drug Administration and the National Cancer Institute in the US, and 
similar organizations if other countries are involved in the study. 
• 
The National Cancer Institute will obtain information for this clinical trial under data 
collection authority Title 42 U.S.C. 285. 
 
Where can I get more information?  
 
You may visit the NCI Web site at http://cancer.gov/ for more information about studies or 
general information about cancer. You may also call the NCI Cancer Information Service to get 
the same information at: 1-800-4-CANCER (1-800-422-6237).  
 
A description of this clinical trial will be available on http://www.clinicaltrials.gov as required by 
U.S. law. This Web site will not include information that can identify you. At most, the Web site 
will include a summary of the results. You can search this Web site at any time. 
 
Who can answer my questions about this study? 
You can talk to the <name>, at <telephone number> about any questions or concerns you have 
about this study or to report side effects or injuries. 
 
 
This section is about optional studies you can choose to take part in.  
This part of the consent form is about optional studies that you can choose to take part in. You 
will not get health benefits from any of these studies. The researchers leading this optional 
study hope the results will help other people with cancer in the future. 
 
The results will not be added to your medical records, and you or your study doctor may not 
know the results. You will not be billed for these optional studies.  
 
You can still take part in the main study even if you say ‘no’ to any or all of these studies. If you 
sign up for but cannot complete any of the studies for any reason, you can still take part in the 
main study. 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
67 
 
Optional Specimen Collections for Laboratory Studies and/or Biobanking for 
Possible Future Studies 
 
Researchers are trying to learn more about cancer and other health problems. Much of this 
research is done using specimens from your biopsies, blood, and urine. Through these studies, 
researchers hope to find new ways to prevent, detect, treat, or cure health problems.  
 
Some of these studies may be about genes. Genes carry information about features that are 
found in you and in people who are related to you. Researchers are interested in the way that 
genes affect how your body responds to treatment. 
 
If you choose to take part, your blood, your urine, and specimens of your tissue will be 
collected. The researchers ask your permission to store and use your specimens and health 
information for medical research. The research that may be done is unknown at this time. 
Storing specimens for future studies is called “biobanking”. The Biobank is being run by the 
Cancer Prevention Network (CPN) at the Mayo Clinic and supported by the National Cancer 
Institute. 
 
WHAT IS INVOLVED?  
 
If you agree to take part, here is what will happen next: 
• About 20 milliliters of blood will be collected from a vein in your arm. 
• A specimen of your urine will be collected. 
• Any tissue specimens collected during your endoscopy exams that are left over after the 
analyses described in the first part of this consent form are complete will be stored for 
research. 
• Your specimens and some related information will be stored in the Biobank at the Mayo 
Clinic along with specimens from other people who choose to take part.  
• The specimens will be kept stored at the Mayo Clinic until the end of the study, when they 
may be transferred to the National Institutes of Health. 
• Qualified researchers can submit a request to use the materials stored in the Biobank. A 
research committee will review each request. There will also be an ethics review to ensure 
that the request is necessary and proper. Researchers will not be given your name or any 
other information that could directly identify you. 
• Neither you nor your doctor will be notified if/when research is conducted using your 
specimens. 
• Some of your genetic and health information may be placed in the central databases that 
may be public, along with information from many other people. Information that could 
directly identify you will not be included. 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
68 
 
WHAT ARE THE POSSIBLE RISKS?  
  
• The most common risks related to drawing blood from your arm are brief pain and possibly 
a bruise.  
• There are no known risks associated with collection of urine. 
• The most common risks related to the biopsy collection are bleeding and nausea, or other 
symptoms, as the drugs used to make you more comfortable during the procedure wear off. 
There is a small risk of a hole in your throat or stomach. 
• There is a risk that someone could get access to the personal information in your medical 
records or other information we have stored about you.  
• There is a risk that someone could trace the information in a central database back to you. 
Even without your name or other identifiers, your genetic information is unique to you. The 
researchers believe the chance that someone will identify you is very small, but the risk may 
change in the future as people come up with new ways of tracing information.  
• A new Federal law, called the Genetic Information Nondiscrimination Act (GINA), generally 
makes it illegal for health insurance companies, group health plans, and most employers to 
discriminate against you based on your genetic information. This law generally will protect 
you in the following ways:        
o Health insurance companies and group health plans may not request your genetic 
information that we get from this research.  
o Health insurance companies and group health plans may not use your genetic 
information when making decisions regarding your eligibility or premiums.        
 
Employers with 15 or more employees may not use your genetic information that we get from 
this research when making a decision to hire, promote, or fire you or when setting the terms of 
your employment. All health insurance companies and group health plans must follow this law 
by May 21, 2010. All employers with 15 or more employees must follow this law as of 
November 21, 2009.  
 
Be aware that this new Federal law does not protect you against genetic discrimination by 
companies that sell life insurance, disability insurance, or long-term care insurance. There are 
laws against the misuse of genetic information, but they may not give full protection. New 
health information about inherited traits that might affect you or your blood relatives could be 
found during a study. The researchers believe the chance these things will happen is very small, 
but cannot promise that they will not occur. 
 
 
HOW WILL INFORMATION ABOUT ME BE KEPT PRIVATE?  
 
Your privacy is very important to the researchers and they will make every effort to protect it. 
Here are just a few of the steps they will take: 
• When your specimen is sent to the researchers, no information identifying you (such as 
your name or social security number) will be sent. Specimens will be identified by a unique 
study code only.  

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
69 
 
• The list that links the unique code to your name will be kept separate from your specimen 
and health information. Any Biobank and National Cancer Institute staff with access to the 
list must sign an agreement to keep your identity confidential. 
• Researchers to whom the National Cancer Institute sends your specimen and information 
will not know who you are. They must also sign an agreement that they will not try to find 
out who you are. 
• Information that identifies you will not be given to anyone, unless required by law. 
• If research results are published, your name and other personal information will not be 
used. 
 
WHAT ARE THE POSSIBLE BENEFITS?  
 
You will not benefit from taking part. The researchers, using the specimens from you and 
others, might make discoveries that could help people in the future. 
 
ARE THERE ANY COSTS OR PAYMENTS?  
 
There are no costs to you or your insurance. You will not be paid for taking part; however, you 
may receive some funds to defray some of the cost of participating (e.g., parking, child care). If 
any of the research leads to new tests, drugs, or other commercial products, you will not share 
in any profits. 
 
WHAT IF I CHANGE MY MIND?  
 
If you decide you no longer want your specimens to be used, you can call the study doctor,  
<name>, at <telephone number> who will let the researchers know. Then, any specimen that 
remains in the bank will no longer be used. Specimens or related information that have already 
been given to or used by researchers will not be returned. 
 
WHAT IF I HAVE MORE QUESTIONS?  
 
If you have questions about the use of your specimens for research, contact the study doctor, 
<name>, at <telephone number>. 
 
Please circle your answer to show whether or not you would like to take part in each option: 
 
SPECIMENS AND RESULTS FOR THE LABORATORY STUDIES: 
 
 
I agree that my study doctors, or their representative, may contact me or my physician to see if 
I wish to learn about results from this study. 
 
 
YES 
 
NO 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
70 
 
 
 
SPECIMENS AND INFORMATION FOR FUTURE RESEARCH STUDIES: 
 
 
My blood, urine, and/or tissue specimens and related information may be kept in a Biobank for 
use in future to learn about, prevent, treat, or cure cancer and other health problems. 
 
 
YES 
 
NO 
 
 
The information from my tobacco and alcohol use questionnaires may be used in future health 
research. 
 
 
YES 
 
NO 
 
 
My blood, urine, and/or tissue specimens and related information may be given to researchers 
at outside institutions 
 
YES 
 
NO 
 
 
I agree that my study doctors, or their representative, may contact me or my physician to see if 
I wish to participate in other research in the future. 
 
 
YES 
 
NO 
 
This is the end of the section about optional studies. 
 
 
 
 
 
 
 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
71 
 
My Signature Agreeing to Take Part in the Main Study 
I have read this consent form or had it read to me. I have discussed it with the study doctor and 
my questions have been answered. I will be given a signed copy of this form. I agree to take 
part in the main study and any additional studies where I circled “yes.”  
 
Participant’s signature ________________________________ 
 
Date of signature_____________________________________ 
 
 
Signature of person(s) conducting the informed consent discussion ______________________ 
 
Date of signature_________________________________  
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
72 
 
Study Calendar 
Time Point/Visit 
Tests and Procedures 
Screening 
• Sign informed consent document 
• Physical exam with review of vital signs (pulse, blood pressure, height, 
weight, temperature) 
• Review of existing symptoms and medications you are taking 
• Alcohol and Tobacco Use Assessment 
• Review of your medical history 
• Blood and urine tests 
• Optional blood and urine collection for research 
• Pregnancy test, if applicable 
EGD 
• Esophagogastroduodenoscopy (EGD) and a lower gastrointestinal (GI) 
exam with biopsies 
Registration 
• Receive instructions for completing diaries and taking medication 
• Receive 3-month supply of study drug 
Day 1 
• Starting on Day 1, take study drug with water once a week, at about 
the same date and time, at least one hour before or two hours after 
eating any food. 
Month 1 
• Physical exam with review of vital signs (pulse, blood pressure, height, 
weight, temperature) 
• Review of side effects and symptoms you are experiencing and any 
medications you are taking 
• Blood and urine tests 
Months 2, 4, 5 
• Phone call to see how you are doing, ask about side effects, and ask 
about any medications you are taking 
Month 3 
• Physical exam with review of vital signs (pulse, blood pressure, height, 
weight, temperature) 
• Review of side effects and symptoms you are experiencing and any 
medications you are taking 
• Blood and urine tests 
• Optional blood and urine collection for research 
• Pregnancy test, if applicable 
• Collect your diaries and any unused study agent 
• Receive 3-month supply of study agent and new diaries 
Month 6  
(or early study 
termination) 
• Physical exam with review of vital signs (pulse, blood pressure, height, 
weight, temperature) 
• Review of side effects and symptoms you are experiencing and any 
medications you are taking 
• Blood and urine tests 
• Optional blood and urine collection for research 
• Pregnancy test, if applicable 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
73 
 
• Collect your diaries and any unused study agent 
• Follow up assessment of your alcohol and tobacco use 
• Esophagogastroduodenoscopy (EGD) and possibly a lower 
gastrointestinal (GI) exam with biopsies 
• Questionnaire (Was It Worth It), which will take about 5 minutes 
Month 7 
• Phone call or clinical visit to see how you are doing, ask about side 
effects, and ask about any medications you are taking. 
• If any of the blood test results at Month 6 were abnormal, they will be 
repeated. 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
74 
 
APPENDIX A 
Performance Status Criteria 
 
ECOG Performance Status Scale 
 
Grade 
Descriptions 
0 
Normal activity. Fully active, able to carry on all pre-
disease performance without restriction. 
1 
Symptoms, but ambulatory. Restricted in physically 
strenuous activity, but ambulatory and able to carry 
out work of a light or sedentary nature (e.g., light 
housework, office work). 
2 
In bed <50% of the time. Ambulatory and capable of 
all self-care, but unable to carry out any work 
activities. Up and about more than 50% of waking 
hours. 
3 
In bed >50% of the time. Capable of only limited self-
care, confined to bed or chair more than 50% of 
waking hours. 
4 
100% bedridden. Completely disabled. Cannot carry 
on any self-care. Totally confined to bed or chair. 
5 
Dead. 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
75 
 
 
APPENDIX B 
Medication and Symptom Diary 
 
Participant ID ____________________________ Study physician ______________________ 
 
Instructions:  This is a checklist for you to use to record taking your study drug. 
Please remember that the study drug is to be taken without food. Do not eat for 2 hours before 
you take the medication or 1 hour after you take the medication.  One suggestion would be to 
take the medication when you first get up in the morning, and then wait at least 1 hour before 
you have breakfast.  On the back of this form, please note any side effects or symptoms you 
experience and any new medications (prescription, over-the-counter, or supplements).  
 
Week 
Date drug 
was taken 
Time drug was 
taken 
Fasting? 
Yes/No 
Time and date of last meal 
Example: 
 Week 1 
11/21/2018 
6:15 a.m. 
Yes 
11/20/2018 6:30 p.m. 
 Week 1 
 
 Am 
 Pm 
 
 
 Week 2 
 
 Am 
 Pm 
 
 
 Week 3 
 
 Am 
 Pm 
 
 
 Week 4 
 
 Am 
 Pm 
 
 
 Week 5 
 
 Am 
 Pm 
 
 
 Week 6 
 
 Am 
 Pm 
 
 
 Week 7 
 
 Am 
 Pm 
 
 
 Week 8 
 
 Am 
 Pm 
 
 
 Week 9 
 
 Am 
 Pm 
 
 
 Week 10 
 
 Am 
 Pm 
 
 
 Week 11 
 
 Am 
 Pm 
 
 
 Week 12 
 
 Am 
 Pm 
 
 
 Week 13 
 
 Am 
 Pm 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
76 
 
 Week 14 
 
 Am 
 Pm 
 
 
 Week 15 
 
 Am 
 Pm 
 
 
 Week 16 
 
 Am 
 Pm 
 
 
 Week 17 
 
 Am 
 Pm 
 
 
 Week 18 
 
 Am 
 Pm 
 
 
 Week 19 
 
 Am 
 Pm 
 
 
 Week 20 
 
 Am 
 Pm 
 
 
 Week 21 
 
 Am 
 Pm 
 
 
 Week 22 
 
 Am 
 Pm 
 
 
 Week 23 
 
 Am 
 Pm 
 
 
 Week 24 
 
 Am 
 Pm 
 
 
 Week 25 
 
 Am 
 Pm 
 
 
 Week 26 
 
 Am 
 Pm 
 
 
 
Remember:  There are a few foods, medications, and activities that may have an impact on the 
effectiveness of the study drug. Please: 
• If you use medications for acid reflux or heartburn symptoms, check with your study 
doctor to make sure you’re using the correct medication.  Do not take any reflux or 
heartburn medication on the day before or the day of taking your study drug, erlotinib. 
• Avoid grapefruit-containing products such as grapefruits, grapefruit juice, and any sodas 
that contain grapefruit juice (Fresca® and Squirt®). 
• You must not smoke or use any tobacco products. Urine tests will be done to monitor 
the amount of tobacco and smoke you are exposed to. 
• Be sure to inform the study team of any new medications, including over-the-counter 
medications, prescription drugs, and dietary supplements. 
• Do not take more than 81 mg (1 baby aspirin) daily or 650 mg (2 adult tablets) weekly of 
aspirin or other NSAIDS. 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
77 
 
Side Effects and Symptoms:  Please list any side effects or symptoms you experience, 
including the dates they started and the dates they stopped. Please list any other medications 
you took, including starting and stopping dates.   If you experience a severe rash or shortness-
of-breath, contact your study doctor right away. 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
78 
 
 
APPENDIX C 
Was It Worth It (WIWI) Questionnaire 
 
Visit type (Time point): _________________________ 
 
             ------------------------------------------------------------------ 
Participating in a clinical trial / research study is a personal choice and an individual 
experience.  We would like to get your feedback on your experience in this research study.  
Please respond to the following questions as indicated. 
 
Directions:  Please answer each question by circling Y (for yes), N (for no), or U (for uncertain). 
 
 
Was it worthwhile for you to participate in this research study? 
 
       Y    N 
U 
 
 
If you had to do it over, would you participate in this research study again?     Y    N 
U 
 
 
Would you recommend participating in this research study to others? 
      Y 
   N 
U 
 
 
Directions:  Circle one response 
 
 
Overall, did your quality of life change by participating in this research study? 
 
 
 
It improved 
               It stayed the same 
 
It got worse 
 
 
 
Overall, how was your experience of participating in this research study?  
 
 
 
Better than I expected 
The same as I expected 
Worse than I expected 
 
 
If there was one thing that could have been done to improve your experience in this research 
study, what would it be? 
 
 
 
 
Would you like to talk to someone about your concerns (circle one response)?     Yes   No 
 
_______________________________________   ___________________________________________ 
Signature 
                                                              Date 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
79 
 
Appendix D. Alcohol Assessment: Baseline 
 
 
Instructions:  For the following questions about drinking alcoholic beverages, a drink means a 12 oz. beer, a 5 oz. glass of wine, 
or one and a half ounces of liquor. 
1. 
In your entire life, have you had at least 12 drinks of any kind of alcoholic beverage? (check one) 
 Yes 
 No (End) 
 Choose not to answer (End) 
 Don’t know/Not sure 
(If No or Choose not to answer), stop assessment 
 
2. 
In the past 12 months, on average, how often did you drink any type of alcoholic beverage?  (Enter the number of days you 
drank based on the timeframe checked below.  Enter 0 if you never drank and skip to Question 6.) _______ 
(If more than 0, check one) 
 Week  
 Month 
 Year 
 Choose not to answer 
 Don’t know/Not sure 
 
3. 
In the past 12 months, on those days that you drank alcoholic beverages, on average, how many drinks did you have per 
day?  
(Enter the average number of drinks per day)_______ 
(If no answer, check one) 
 Choose not to answer 
 Don’t know/Not sure 
 
4. 
In the past 12 months, on how many days did you have 5 or more drinks of any alcoholic beverage?   
(Enter the number of days you had 5 or more drinks, or enter 0 if none.)________ 
(If no answer, check one) 
 Choose not to answer 
 Don’t know/Not sure 
 
5. 
Was there ever a time or times in your life when you drank 5 or more drinks of any kind of alcoholic beverage almost every 
day?  
       (check one) 
 Yes 
 No  
 Choose not to answer 
 Don’t know/Not sure 
 
6. 
If you do not currently drink alcoholic beverages, but did in the past, how long has it been since you last drank regularly?  
       (check one) 
 Within the past month (0 to 1 month ago) 
 Between 1 and 3 months (1 to 3 months ago) 
 Between 3 and 6 months (3 to 6 months ago) 
 Between 6 and 12 months (6 to 12 months ago) 
 Between 1 and 5 years (1 to 5 years ago) 
 Between 5 and 15 years (5 to 15 years ago) 
 More than 15 years ago  
 Don’t know/Not sure 
 Never drank regularly 
 Choose not to answer 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
80 
 
Alcohol Assessment: Baseline (continued) 
 
 
7. 
At the heaviest point, either now or in the past, on the days when you drank, about how many drinks did you drink a day 
on the average?  (Enter the number of drinks a day)________ 
       (If no answer, check one)  
 Choose not to answer 
 Don’t know/Not sure 
 
8. 
How many years have you been drinking (or did drink) regularly?    ______ years 
(If no answer, check one) 
 Choose not to answer 
 Don’t know/Not sure  
 
9. 
At what age did you begin drinking regularly?   ______ years of age 
 
(If no answer, check one) 
 Choose not to answer 
 Don’t know/Not sure  
 
10. What type(s) of alcohol do you drink?  
 
Wine  
(check one) 
Yes     
No    
 Choose not to answer 
Liquor   
(check one) 
Yes     
No    
 Choose not to answer 
Beer   
(check one) 
Yes     
No    
 Choose not to answer 
Wine cooler   
(check one) 
Yes     
No    
 Choose not to answer 
 
 
 
 
 
 
 
____________________________   ___________________________ 
Investigator Signature  
 
Date 
 
 
 
 
 
 
 
 
 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
81 
 
Appendix D. Alcohol Assessment: Follow-Up 
 
 
 
Instructions:  For the following questions about drinking alcoholic beverages, a drink means a 12 oz. beer, a 5 oz. glass of wine, 
or one and a half ounces of liquor. 
 
 
1. During the past 30 days, did you drink any alcoholic beverages?  (check one) 
 Yes 
 No (End) 
 Choose not to answer (End) 
 Don’t know/Not sure 
    (If No or Choose not to answer, stop assessment) 
 
2. During the past 30 days, how many days per week or per month did you drink any alcoholic beverages, on the average?  
(Enter number of days you drank based on the timeframe checked below.  Enter 0 if you did not drink.) ______ 
(If more than 0), specify (check one) 
 Week  
 Month 
 Choose not to answer 
 Don’t know/Not sure 
 
3. On the days when you drank, on average, about how many drinks did you have?    
(Enter the average number of drinks you had per day.) _______ 
(If no answer, check one) 
 Choose not to answer 
 Don’t know/Not sure 
 
4. In the past 30 days, on how many days did you have 5 or more drinks per day?   _____________ 
 (Enter the number of days you had 5 or more drinks, or enter 0 if none) 
(If no answer, check one) 
 
 None 
 
 Choose not to answer  
 
 Do not know/Not sure 
 
 
 
 
____________________________   ___________________________ 
Investigator Signature  
 
Date 
 
 
 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
82 
 
Appendix D. Tobacco Assessment: Baseline 
 
Section A. Basic Cigarette Use Information 
1. Have you smoked at least 100 cigarettes (5 packs = 100 cigarettes) in your entire life? 
Yes  
 Choose not to answer → Skip to Section B 
 
 No → Skip to Section B 
 Don’t know/Not sure → Skip to Section B 
 
2. How old were you when you first smoked a cigarette (even one or two puffs)?    _______ Years old 
 
(If no answer, check one) 
  
Choose not to answer       
Don’t know/Not sure 
 
3. How old were you when you first began smoking cigarettes regularly?   _______ Years old 
 
   (If no answer, check one) 
     
Refused        
Don’t know/Not sure     
Check here if you have never smoked cigarettes regularly. 
 
4. How many total years have you smoked (or did you smoke) cigarettes? Do not count any time you may have stayed off 
cigarettes.       
  (If you smoked less than one year, write “1.”)  ______ Years 
 
 
Choose not to answer       
Don’t know/Not sure 
 
5. On average when you have smoked, about how many cigarettes do you (or did you) smoke a day? (A pack usually has 20 
cigarettes in it).   _____ Number of cigarettes per day 
(If no answer, check one) 
 
Choose not to answer       
Don’t know/Not sure 
 
6. Do you NOW smoke cigarettes? (check one) 
 Everyday 
 Some days 
 Choose not to answer → Skip to question 8 
 Not at all → Skip to question 8 
 
7.  How soon after you wake up do you smoke your first cigarette? (check one) 
  Within 30 minutes            
  After 30 minutes      
 Choose not to answer 
 
8. How long has it been since you last smoked a cigarette (even one or two puffs)? First check which one of the following choices 
applies to you. Then, if applicable, write a number on the line for how many days, weeks, months, or years it has been since your 
last cigarette. 
I smoked a cigarette today (at least one puff)   (check one) 
Yes     
No 
1-7 days   (check one)   
Yes     
No 
(If yes), Number of days since last cigarette ________ 
Less than 1 month (check one)   
Yes     
No 
(If yes), Number of weeks since last cigarette _________ 
Less than 1 year (check one)   
Yes     
No 
(If yes), Number of months since last cigarette __________ 
More than 1 year (check one)   
Yes     
No 
(If yes), Number of years since last cigarette ___________ 
Don’t know/Don’t remember   (check one)   
Yes     
No 
Choose not to answer 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
83 
 
Tobacco Assessment: Baseline (continued) 
Section B. Use of Other Forms of Tobacco 
 
9.  Have you ever used other forms of tobacco, not including cigarettes? (check one) 
 Yes    
 Choose not to answer 
 No → Skip to Section C 
 
10.  How often do you/did you use other forms of tobacco? 
Every day   (check one)     
Yes     
No       (If yes), Number of times per day ________ 
Some days   (check one)   
Yes     
No     (If yes), Number of days _______  
(If yes), Per (select one)     
 Week       
 Month    
Year 
 
11. Which of the following products have you ever used regularly?  (Mark yes, no., or choose not to answer for all choices) 
Cigarettes 
(check one)  
Yes     
No    
 Choose not to answer 
Traditional cigars, cigarillos or filtered cigars 
(check one)  
Yes     
No    
 Choose not to answer 
Hookah 
(check one)  
Yes     
No    
 Choose not to answer 
Bidis 
(check one)  
Yes     
No    
 Choose not to answer 
Snus 
(check one)  
Yes     
No    
 Choose not to answer 
E-cigarettes or other electronic nicotine delivery system 
(check one)  
Yes     
No    
 Choose not to answer 
Pipes 
(check one)  
Yes     
No    
 Choose not to answer 
Waterpipe 
(check one)  
Yes     
No    
 Choose not to answer 
Clove cigarettes or kreteks 
(check one)  
Yes     
No    
 Choose not to answer 
Smokeless tobacco (like dip, chew, or snuff) 
(check one)  
Yes     
No    
 Choose not to answer 
Paan with tobacco, gutka, zarda, khaini 
(check one)  
Yes     
No    
 Choose not to answer 
Other, please specify: _________________________ 
 
 
12. If you do not currently use other forms of tobacco, but did in the past, how long has it been since you last used other forms 
of tobacco regularly? (check one) 
 Within the past month (0 to 1 month ago) 
 Between 1 and 5 years (1 to 5 years ago) 
 Between 1 and 3 months (1 to 3 months ago) 
 Between 5 and 15 years (5 to 15 years ago) 
 Between 3 and 6 months (3 to 6 months ago) 
 More than 15 years ago 
 Between 6 and 12 months (6 to 12 months ago) 
 Don’t know/Not sure 
 Never used other forms of tobacco regularly     
 Choose not to answer 
 
Section C. Second-Hand Smoke Exposure 
 
13. Are you currently living with a smoker?  (check one) 
Yes       
No       
 Choose not to answer 
  
14. In the past 30 days, have you lived in a place where other people smoked cigarettes indoors?  (check one) 
Yes       
No       
 Choose not to answer 
 
15. In the past 30 days, have you worked in a place where other people smoked cigarettes indoors? (check one) 
Yes       
No       
 Choose not to answer 
 
16. Thinking of all your childhood and adult years, have you ever lived in a place where other people smoked cigarettes 
indoors? (check one) 
Yes → In total, for about how many years? _______ If less than 1, write “1.”   
No        
 Choose not to answer 
 
17. Thinking of all the years you have worked, have you ever worked in a place where other people smoked cigarettes indoors?    
(check one) 
Yes → In total, for about how many years? _______ If less than 1, write “1.”   
No        
           
 Choose not to answer              ____________________________   ___________________________ 
                                                            Investigator Signature 
 
 
Date 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
84 
 
Appendix D. Tobacco Assessment: Follow-Up 
 
1. Do you NOW smoke cigarettes? (check one) 
 Everyday 
 Some days 
 Choose not to answer→ Skip to Question 4. 
 Not at all → Skip to Question 4. 
 
2. On average, when you smoked, about how many cigarettes do you (or did you) smoke a day? (A pack usually has 20 
cigarettes in it).    
_____ Number of cigarettes per day 
(If no answer, check one) 
Choose not to answer      
Don’t know/Not sure 
 
3. How long has it been since you last smoked a cigarette (even one or two puffs)?   First check which one of the following 
choices applies to you. Then, if applicable, write a number on the line for how many days, weeks, months, or years it has been 
since your last cigarette. 
I smoked a cigarette today (at least one puff)   (check one)   
Yes     
No 
1-7 days    (check one)   
Yes     
No 
 
(If yes), Number of days since last cigarette _____ 
Less than 1 month   (check one)   
Yes     
No 
 
(If yes), Number of weeks since last cigarette _____ 
Less than 1 year   (check one)   
Yes     
No 
 
(If yes), Number of months since last cigarette _____ 
More than 1 year   (check one)   
Yes     
No 
 
(If yes), Number of years since last cigarette _____ 
Don’t know/Don’t remember   (check one)   
Yes     
No 
Choose not to answer 
 
 
4. Since your last visit, have you used other forms of tobacco, not including cigarettes?  (check one) 
 Yes 
 Choose not to answer (End) 
  No (End)        (If no), stop assessment 
 
5. How often do you/did you use other forms of tobacco?  
Every day    (check one)   
Yes     
No      (If yes), Number of times per day ________ 
Some days   (check one)   
Yes     
No     (If yes), Number of days ________  
 
                                                               (If yes), per (select one)    
Week    
Month    
Year 
     
Choose not to answer 
 
6.   Since your last visit, which of the following products have you used?  (Mark yes or no for all choices) 
Cigarettes 
(check one)  
Yes     
No    
 Choose not to answer 
Traditional cigars, cigarillos or filtered cigars 
(check one)  
Yes     
No    
 Choose not to answer 
Hookah 
(check one)  
Yes     
No    
 Choose not to answer 
Bidis 
(check one)  
Yes     
No    
 Choose not to answer 
Snus 
(check one)  
Yes     
No    
 Choose not to answer 
E-cigarettes or other electronic nicotine delivery system 
(check one)  
Yes     
No    
 Choose not to answer 
Pipes 
(check one)  
Yes     
No    
 Choose not to answer 
Waterpipe 
(check one)  
Yes     
No    
 Choose not to answer 
Clove cigarettes or kreteks 
(check one)  
Yes     
No    
 Choose not to answer 
Smokeless tobacco (like dip, chew, or snuff) 
(check one)  
Yes     
No    
 Choose not to answer 
Paan with tobacco, gutka, zarda, khaini 
(check one)  
Yes     
No    
 Choose not to answer 
Other, please specify: _________________________ 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
85 
 
Tobacco Assessment: Follow-Up (continued) 
 
7. If you do not currently use other forms of tobacco, but did in the past, how long has it been since you last used other forms 
of tobacco regularly? (check one) 
 Within the past month (0 to 1 month ago) 
 Between 1 and 3 months (1 to 3 months ago) 
 Between 3 and 6 months (3 to 6 months ago) 
 Between 6 and 12 months (6 to 12 months ago) 
 Between 1 and 5 years (1 to 5 years ago) 
 Between 5 and 15 years (5 to 15 years ago) 
 More than 15 years ago 
 Don’t know/Not sure 
 Choose not to answer 
 Never used other forms of tobacco regularly 
 
The following instructions pertain to questions 8 -10.  During each of the following time frames, please indicate whether you 
smoked cigarettes every day, some days, or not at all. 
 
8.  During study treatment (check one) 
 Smoked every day 
 Smoked some days 
 Did not smoke at all 
 Don’t know/not sure 
 Choose not to answer 
 Not applicable  
 
9.  After the end of study treatment (check one)  
 Smoked every day 
 Smoked some days 
 Did not smoke at all 
 Don’t know/not sure 
 Choose not to answer 
 Not applicable (I have not completed the study treatment) 
 
 
 
10.  Since your last visit to this clinic (check one) 
 
 Smoked every day 
 Smoked some days 
 Did not smoke at all 
 Don’t know/not sure 
 Choose not to answer 
 Not applicable (This is my first visit to this clinic) 
 
 
____________________________   ___________________________ 
Investigator Signature  
 
Date 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
86 
 
Appendix E. Alcohol and Tobacco Cessation Resources 
National and local resources to help with alcohol abuse and alcoholism 
NIAAA’s online guide Treatment for Alcohol Problems: Finding and Getting Help is written for 
individuals, and their family and friends, who are looking for options to address alcohol 
problems. It is intended as a resource to understand what treatment choices are available and 
what to consider when selecting among them. 
https://pubs.niaaa.nih.gov/publications/treatment/treatment.htm 
Other resources: 
National Institute on Alcohol Abuse and Alcoholism www.niaaa.nih.gov  
301–443–3860  
National Institute on Drug Abuse www.nida.nih.gov  
301–443–1124  
National Clearinghouse for Alcohol and Drug Information www.samhsa.gov  
1–800–729–6686  
Substance Abuse Treatment Facility Locator www.findtreatment.samhsa.gov  
1–800–662–HELP  
Alcoholics Anonymous (AA) www.aa.org  
212–870–3400 or check your local phone directory under “Alcoholism”  
Moderation Management www.moderation.org 
212–871–0974  
Secular Organizations for Sobriety www.sossobriety.org  
323–666–4295  
SMART Recovery www.smartrecovery.org  
440–951–5357  
Women for Sobriety www.womenforsobriety.org  
215–536–8026  
Al-Anon Family Groups www.al-anon.alateen.org  
1–888–425–2666 for meetings  
Adult Children of Alcoholics www.adultchildren.org 
310–534–1815  
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
87 
 
National and local resources to help with quitting smoking 
NCI’s Smokefree.gov offers science-driven tools, information, and support that has helped 
smokers quit. You will find state and national resources, free materials, and quitting advice 
from NCI. 
Smokefree.gov was established by the Tobacco Control Research Branch of NCI, a component 
of the National Institutes of Health, in collaboration with the Centers for Disease Control and 
Prevention and other organizations. 
Publications available from the Smokefree.gov Web site include the following: 
• 
Clearing the Air: Quit Smoking Today for smokers interested in quitting. 
• 
Clear Horizons for smokers over age 50. 
• 
Forever Free™  for smokers who have recently quit. 
• 
Forever Free for Baby and Me™, in English and Spanish, for pregnant smokers who have 
recently quit. 
• 
Pathways to Freedom: Winning the Fight Against Tobacco for African American smokers. 
NCI’s Smoking Quitline at 1–877–44U–QUIT (1–877–448–7848) offers a wide range of services, 
including individualized counseling, printed information, referrals to other resources, and 
recorded messages. Smoking cessation counselors are available to answer smoking-related 
questions in English or Spanish, Monday through Friday, 8:00 a.m. to 8:00 p.m., Eastern Time. 
Smoking cessation counselors are also available through LiveHelp, an online instant messaging 
service. LiveHelp is available Monday through Friday, 8:00 a.m. to 11:00 p.m., Eastern Time. 
Your state has a toll-free telephone quitline. Call 1–800–QUIT–NOW (1–800–784–8669) to get 
one-on-one help with quitting, support and coping strategies, and referrals to resources and 
local cessation programs. The toll-free number routes callers to state-run quitlines, which 
provide free cessation assistance and resource information to all tobacco users in the United 
States. This initiative was created by the Department of Health and Human Services. For more 
information about quitlines, speak to an expert on the Smokefree.gov Web site. 
 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
88 
 
Appendix F.  Diary of Medications Used for Acid Reflux Symptoms 
 
Participant ID ____________________________ Study physician ______________________ 
 
Instructions:  Use this diary to record any medications used for symptoms related to acid reflux 
or upset stomach.  Use the back of this page for any other notes or comments.   
 
REMEMBER:  These medications may interfere with the effectiveness of erlotinib.  You are 
asked to avoid these medications on the day before and the day you actually take your weekly 
erlotinib.  Please let your study team know if you have any questions or problems. 
 
Date/Time 
Name of antacid taken 
Dose 
Name of H2 receptor 
agonist 
Dose 
Example: 1/11/2018 
8:00 p.m. 
Tums – Extra strength 
2 tablets = 1500 
mg 
 
 
Example:  1/19/2018 
8:00 p.m. 
 
 
ranitidine 
150 mg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

MAY2016-07-01 
Version 3.0, Amendment 8 
July 22, 2019 
89 
 
Date/Time 
Name of antacid taken 
Dose 
Name of H2 receptor 
agonist 
Dose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
_____________________________________________   ___________________ 
Participant signature                                                                  Date